===== DISCHARGE NOTE =====
note_id=17093667-DS-22 | hadm_id=21779822

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
syncope
 
Major Surgical or Invasive Procedure:
None

 
History of Present Illness:
HISTORY OF PRESENTING ILLNESS: 
___ is a ___ year old man with relapsed mantle cell
lymphoma who is admitted from the ED after syncopizing during
rituximab infusion in clinic.

Patient was diagnosed with relapsed MCL during admission in
___ in the setting of 'convulsive syncope', which patient 
has
had on and off for at least a year. That admission was notable
for extensive workup including telemetry monitoring, PPM
interrogation, EEG, and CTH - all negative except new lacunar
infarct on CT. MRI brain was notable for right occipital FLAIR
hyperintense enhancement; LP showed elevated protein but 
negative
for lymphoma. He was later admitted to the ICU from ___ to
___ for septic shock and pneumonia; he completed treatment
with cefpodoxime and azithromycin. 

He presented to clinic today to initate treatment for his
relapsed MCL with rituximab. Per nursing clinic note:

"[Patient] given premeds as ordered, Rituxan started at ___
infusion rate, was up to 100mg/hr and pt's face slightly 
flushed.
VSS. No other sx. Pt then called to say he was nauseated approx.
20mins into the 100mg/hr rate. When entered pts room pt was 
ashen
and staring straight ahead and eyes rolled upward. Started
vomiting and unresponsive for a few seconds.  Suction obtained
and pt put on his side. Immediately became responsive again. No
further seizure activity Rituxan was stopped immediately.  Seen
by Dr. ___ NP. Pt [was] sent to ED." 

Patient denies any bowel or bladder incontinence and there was 
no
tongue biting. His wife notes he had some bilateral arm shaking.
He awoke without post-ictal state and currently feels well.

Since his prior admission he has been generally weak and 
fatigued
but without acute complaint. No fevers or chills. No headaches 
or
diplopia. No dysphagia. No recent URTI symptoms although he has 
a
chronic cough. No CP or SOB. No N/V/D. Normal BM today. He 
denies
orthostatic sytmpoms. No new leg pain or swelling. He has
intermittent positional neuropathy in his left leg. He reports 
he
passes out once every few months. His wife reports his last
episode was in ___. 

In the ED, initial VS were pain 0, T 95.9, HR 80, BP 110/78, RR
18, O2 97%RA. Labs notable for Na 141, K 5.1, HCO3 20, Cr 1.2,
WBC 6.2, HCT 37.1, PLT 78. LFT's and urate from earilier in day
were normal. CXR showed no acute process. EKG showed sinus 
rhythm
with PAC's. EP was consulted, who felt cardgiogenic cause was
unlikely. He was admitted to ___ for further management.

 
Past Medical History:
ONCOLOGIC HISTORY:
 * ___ - C1 CHOP
 * ___ - Admitted urgently due to choroidal cellular
infiltrate in the left eye concerning for CNS involvement from
his Mantle Cell lymphoma/leukemia.  MRI imaging consistent with
this. 
 * ___ - High dose methotrexate, complicated by acute renal
insufficiency with creatinine peaking at 2.2 felt most likely
from precipitation in the renal tubules.  Creatinine has 
trending
downward, stabilizing at 1.5. Discharged on ___.
 * ___ and ___ - Received Rituxan in divided doses
with mild reaction. 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to his age and renal function; received 2 doses on ___, 1 dose
on ___ and 1 dose on ___.  On Neupogen support during nadir,
required transfusion of red cells and platelets.
 * ___ - C2 RCHOP 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to age and renal function.  High dose MTX on hold with renal
insufficiency.
 * ___ - C3 RCHOP
 * Restaging scan shows interval improvement of lymphoma.  MRI 
of
head with resolution of previous enhancement.  
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 due
to age and renal function. 
 * ___ - Repeat LP and IT Ara-C given
 * ___ - High dose cytoxan for stem cell mobilization
 * ___ - Started stem cell collections with Neupogen and
Mozibil and collected ~ 5 million CD34 cells/kg over 4 days.
 .
PAST MEDICAL HISTORY:  
- Mantle cell lymphoma/leukemia
- Heterozygous for Factor V Leiden and low Protein S activity of
39%, repeated on ___, now normal 
- Hypertension
- Prostate hypertrophy 
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- Status post appendectomy
- Status post prostate biopsy (incisional)
- Status post repair of deviated nasal septum

 
Social History:
___
Family History:
No lymphoma or leukemia in family. Mother had bone cancer, died 
at age ___ with also history of ___. Father died at age 
___ with h/o hypertension, stroke. One brother s/p CABG, stroke 
and ETOH use.
 
Physical Exam:
==========================
ADMISSION PHYSICAL EXAM: 
========================== 
VS: T 97.8 HR 89 BP 112/73 RR 18 SAT  97% O2 on RA
GENERAL: Pleasant and generally well appearing man sitting up in
bed in no distress
EYES: Anicteric sclerea, PERLL, EOMI; 
ENT: MMM, Oropharynx clear without lesion, JVD not elevated 
CARDIOVASCULAR: Regular rate and rhythm, no murmurs, rubs, or
gallops
RESPIRATORY: Appears in no respiratory distress, clear to
auscultation bilaterally, no crackles, wheezes, or rhonchi
GASTROINTESTINAL: Normal bowel sounds; nondistended; soft,
nontender without rebound or guarding; no hepatomegaly, no
splenomegaly
MUSKULOSKELATAL: Warm, well perfused extremities without lower
extremity edema; Normal bulk 
NEURO: Alert, oriented, CN III-XII intact, full strength in all
extremities. Cerebellar fxn intact to FTN bilaterally
SKIN: No significant rashes
ACCESS: L antecubital PIV

==========================
DISCHARGE PHYSICAL EXAM
==========================
24 HR Data (last updated ___ @ 1327)
    Temp: 98.2 (Tm 98.3), BP: 99/59 (99-133/59-79), HR: 81
(67-84), RR: 18 (___), O2 sat: 96% (94-97), O2 delivery: ra,
Wt: 189.2 lb/85.82 kg     
GENERAL: NAD
CARDIOVASCULAR: RRR, no murmurs, rubs, or
gallops
RESPIRATORY: Appears in no respiratory distress, clear to
auscultation bilaterally, no crackles, wheezes, or rhonchi
MUSKULOSKELATAL: Warm, well perfused extremities without lower
extremity edema
NEURO: AOx3, CN II-XII grossly intact, hyperreflexia in the ___,
otherwise strength ___ in the UE and ___
SKIN: No significant rashes
ACCESS: L antecubital PIV

 
Pertinent Results:
========================
ADMISSION LABS
========================

___ 02:42PM   LACTATE-1.6
___ 02:35PM   GLUCOSE-130* UREA N-25* CREAT-1.2 SODIUM-141 
POTASSIUM-5.1 CHLORIDE-108 TOTAL CO2-20* ANION GAP-13
___ 02:35PM   CK-MB-2 cTropnT-<0.01
___ 02:35PM   WBC-6.2 RBC-3.95* HGB-12.1* HCT-37.1* MCV-94 
MCH-30.6 MCHC-32.6 RDW-13.7 RDWSD-47.1*
___ 02:35PM   NEUTS-94.3* LYMPHS-2.6* MONOS-1.6* EOS-0.3* 
BASOS-0.2 IM ___ AbsNeut-5.81 AbsLymp-0.16* AbsMono-0.10* 
AbsEos-0.02* AbsBaso-0.01
___ 02:35PM   PLT COUNT-78*
___ 08:35AM   UREA N-24* CREAT-1.1 SODIUM-142 POTASSIUM-4.4 
CHLORIDE-105 TOTAL CO2-26 ANION GAP-11
___ 08:35AM   ALT(SGPT)-22 AST(SGOT)-26 LD(LDH)-204 ALK 
PHOS-97 TOT BILI-0.5
___ 08:35AM   TOT PROT-7.0 ALBUMIN-4.1 GLOBULIN-2.9 
CALCIUM-9.1 MAGNESIUM-2.3 URIC ACID-6.5
___ 08:35AM   TOT PROT-6.6
___ 08:35AM   PEP-NO SPECIFI IgG-650* IgA-193 IgM-139
___ 08:35AM   WBC-5.0 RBC-4.16* HGB-12.6* HCT-39.3* MCV-95 
MCH-30.3 MCHC-32.1 RDW-13.8 RDWSD-47.6*
___ 08:35AM   NEUTS-63.3 ___ MONOS-10.1 EOS-4.4 
BASOS-0.4 IM ___ AbsNeut-3.14 AbsLymp-1.06* AbsMono-0.50 
AbsEos-0.22 AbsBaso-0.02
___ 08:35AM   PLT COUNT-102*

========================
IMAGING STUDIES
========================
CXR ___
No acute cardiopulmonary process.

CTH ___
No acute intracranial abnormality.

Transthoracic Echo ___
No structural cardiac cause of syncope identified. Mild 
symmetric left ventricular
hypertrophy with normal cavity size, and hyperdynamic 
regional/global systolic function.
Posterior mitral valve prolapse with moderate to severe 
holosystolic anteriorly directed mitral
regurgitation. Mild aortic regurgitation. Mild pulmonary artery 
systolic hypertension.

MRI CERVICAL THORACIC ___. No evidence of cord signal abnormality or abnormal 
enhancement. 
2. Moderate to severe degenerative change of the lumbar spine, 
most severe at 
L2-L3 and L3-L4 as described above, including severe loss of 
intervertebral 
disc height, likely chronic mild retrolisthesis, and moderate 
spinal canal 
stenosis secondary to posterior disc protrusion/osteophyte 
complex. 
3. Moderate to severe multilevel lumbar foraminal narrowing, 
most severe at 
L2-L3 and L3-L4. 
4. Mild to moderate degenerative change of the cervical spine, 
most severe at 
C4-C5 and C5-C6, with mild spinal stenosis secondary to 
posterior disc 
protrusions and moderate right-sided foraminal narrowing. 

MRI & MRA BRAIN AND MRA ___. No evidence of acute infarction or hemorrhage. 
2. Previously demonstrated FLAIR hyperintensity and 
leptomeningeal enhancement 
within the medial right occipital lobe is no longer visualized 
on the current 
study. 
3. Stable appearance of a 6 mm focus of of isointense soft 
tissue adjacent to 
brain parenchyma in the region of the right middle cerebellar 
peduncle, 
unchanged compared to multiple prior studies dating back to ___ 
and without 
evidence of abnormal enhancement.  This could represent normal 
brain 
parenchyma, post treatment change, or benign entity such as 
hamartoma. 
4. Diminutive right vertebral artery with chronic occlusion in 
the region of 
the distal V3 segment, unchanged compared to multiple prior MRI 
studies dated 
as early as ___. 
5. Patent circle of ___ without definite evidence of 
stenosis,occlusion,or 
aneurysm. 
6. Patent bilateral cervical carotid arteries without definite 
evidence of 
stenosis, occlusion, or dissection.  Dominant left vertebral 
artery without 
evidence of stenosis or occlusion 

========================
DISCHARGE LABS
========================
___ 09:18AM BLOOD Plt Ct-90*
___ 09:18AM BLOOD Glucose-94 UreaN-19 Creat-1.1 Na-143 
K-4.5 Cl-106 HCO3-25 AnGap-12
___ 07:45PM BLOOD Neuts-59.4 ___ Monos-11.3 Eos-4.0 
Baso-0.2 Im ___ AbsNeut-2.51 AbsLymp-1.04* AbsMono-0.48 
AbsEos-0.17 AbsBaso-0.01
 
Brief Hospital Course:
===============================
PATIENT SUMMARY STATEMENT
===============================
___ man with past medical history of mantle cell 
lymphoma complicated by ocular and CNS involvement (s/p auto 
transplant, maintenance ritux ending ___, now with 
recurrence and was started
on rituximab, a history of recurrent syncope, SSS status post
pacemaker, pAFib (Eliquis) who presents with vasovagal syncope 
which occurred during rituximab infusion.

===============================
ACTIVE ISSUES:
===============================

#Syncope
Patient was 20 minutes into his rituximab infusion when he was 
noted to have a red face. He then developed nausea and this was 
the last thing he remembered. Per nursing, he had moments of 
staring, vomited and then synopsized. He presented to the ED 
where his vitals signs were stable. Of note, patient has already 
received a extensive workup at last hospitalization a few months 
ago. This included an MRI that
showed possible recurrence of CNS lymphoma but with one negative
LP and per discharge summary this was not felt to be consistent
with CNS recurrence. He also had a continuous EEG for 3 days
during the hospitalization that did not show any epileptiform
discharges or seizure activity. Overall this current spell seems 
consistent with the one he was admitted for in ___ and 
likely represents a vasovagal syncope. 

During this admission, his neurologic exam was nonfocal but 
notable for hyperreflexia throughout including clonus in 
bilateral ankles. Brisk reflexes felt likely due to chronic 
cervical spinal disease which was confirmed on MRI spine. 
Patient also had full cardiac work-up including interrogation of 
pacemaker which was normal. TTE without cause for syncope and 
troponins were negative. LP was deferred given no signs of 
infection and low concern for CNS disease. Ultimately, his 
symptoms were felt to be a result of vasovagal syncope with some 
components of orthostatics. Patient was counseled on isometric 
counterpressure maneuvers and will be discharged with 
compression stockings. Patient will require tilt-table test as 
outpatient.

#Recurrent Mantle Cell Lymphoma
Patient was found to have disease relapse in ___ with 
plan to initiate R2 with ritux infusion aborted on ___ due to 
syncope. Rituximab was redosed on ___ uneventfully. Patient to 
hold revlimid till outpatient appointment with Dr. ___. He 
received prophylaxis with acyclovir

#Thrombocytopenia
Not far off of recent baseline; likely related to relapsed
lymphoma. Platelets on discharge were 90k.

===============================
CHRONIC ISSUES
===============================

#Sick sinus syndrome s/p pacemaker
#AFib
Continued home apixiban. EP evaluated pacemaker and felt to be 
functioning appropriately.

#BPH
Continued home tamsulosin.

#HTN
Has been off losartan since recent admission so continued to 
hold this medication.

#Prior CVA
No longer on ASA; Apixiban as above and continued home statin

===============================
TRANSITIONAL ISSUES
===============================
Hg: 11.9
Plts: 90

[]Patient to continue holding revlimid till appointment with Dr. 
___
[]Tilt table testing as outpatient.
[]Patient to follow-up with outpatient neurologist, phone number 
provided in discharge paperwork.
[] Patient to follow-up with Dr. ___ treatment of 
relapsed MCL. 

===============================
CODE: Full (presumed) 
EMERGENCY CONTACT HCP: ___: wife
Phone number: ___
Cell phone: ___
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Acyclovir 400 mg PO Q12H 
2. Apixaban 5 mg PO BID 
3. Atorvastatin 80 mg PO QPM 
4. FoLIC Acid 1 mg PO DAILY 
5. Albuterol Inhaler 2 PUFF IH Q6H:PRN sob 
6. Cyanocobalamin 1000 mcg PO EVERY OTHER DAY 
7. Multivitamins 1 TAB PO DAILY 
8. Tamsulosin 0.4 mg PO QHS 

 
Discharge Medications:
1.  Acyclovir 400 mg PO Q12H  
2.  Albuterol Inhaler 2 PUFF IH Q6H:PRN sob  
3.  Apixaban 5 mg PO BID  
4.  Atorvastatin 80 mg PO QPM  
5.  Cyanocobalamin 1000 mcg PO EVERY OTHER DAY  
6.  FoLIC Acid 1 mg PO DAILY  
7.  Multivitamins 1 TAB PO DAILY  
8.  Tamsulosin 0.4 mg PO QHS  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Vasovagal syncope

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.
Mental Status: Clear and coherent.

 
Discharge Instructions:
Dear Mr. ___,  

It was a pleasure caring for you at ___. 

WHY WAS I IN THE HOSPITAL?  
-You came to the hospital because you passed out while receiving 
your rituximab infusion.

WHAT HAPPENED TO ME IN THE HOSPITAL?  
-While you were here, you had a lot of tests to evaluate why you 
were passing out. Labs were normal, your pacemaker is working 
well and the MRI of your brain and spine did not show any 
cancer. It did show degenerative spinal disease which can happen 
as people age.

- We know you have had these passing out spells before and we 
think this is due to your body overreacting to some triggers 
which lowers your blood pressure causing you to faint. We did 
not find any neurological causes for you passing out.
 
WHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?  
-If you feel like you are about to pass out, please try crossing 
your legs or tensing your lower body muscle. Lying down and 
raising legs may also be beneficial if it can be done safely. We 
will also discharge you with some compression stockings that 
help push blood to the heart to prevent these episodes.

-Please stop taking your Revlimid until you follow-up with Dr. 
___. 

-Please call your neurologist to schedule a follow-up 
appointment within the next 2 months.

-Please continue to take all your medicines and keep your 
appointments.  

We wish you the best!  
Sincerely,  
Your ___ Team
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-20 | hadm_id=21893821

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
Chief Complaint:
Syncope
 
Major Surgical or Invasive Procedure:
Lumbar Puncture
Bone Marrow Biopsy
Lymph Node Biopsy 

 
History of Present Illness:
___ PMH of Mantle cell lymphoma/leukemia with CNS involvement
(s/p auto transplant, maintenance ritux ending ___, HTN,
CVA/CRVO, SSS (s/p PPM), pAFib (Eliquis), Convulsive Syncope, 
who
presented from ___ s/p episode of convulsive
syncope, in light of pathologic rib fracture and diffuse
lymphadenopathy seen on imaging

As per review of notes and discussion with patient and his Wife
___, patient was in his USOH, watching his grandson's holiday
concert at school when he had sudden onset, sharp pain, in his
right lower back, which caused him to feel weak. He leaned over
and passed out in his wifes lap. He remained seated and did not
fall. He had urinary incontinence and some shaking. Upon
awakening he was diaphoretic and projectile vomited a few times
but the pain was gone. He then had complete resolution of all
symptoms, and has been in his USOH since. Denied fever, cough,
rhinorrhea, headache, pain anywhere, difficulty w/
walking/coordination/strength

He was brought to ___ by EMS where he had 3 negative troponins
and EKG which was not concerning for ischemia. Cardiology
interrogated PPM which was working OK and did not show acute
arrhythmia which could have caused episode. Patient was seen by
neurology and EEG was performed (report not in chart), who
thought that vasovagal etiology due to pain was most likely. 

He had Cr of 1.4 (baseline 1.2), which was felt to be ___,
possibly ___ hypovolemia from vomiting so was given IVF and Cr
normalized. 

Patient had CT Chest which revealed new b/l axillary,
peripancreatic, periportal, paraortic and aortocaval
lymphadenopathy concerning for malignancy. He also was found to
have non displaced pathologic fracture of posterior right 
seventh
rib. Accordingly, was transferred to ___ for further
investigation. 
 
Past Medical History:
ONCOLOGIC HISTORY:
 * ___ - C1 CHOP
 * ___ - Admitted urgently due to choroidal cellular
infiltrate in the left eye concerning for CNS involvement from
his Mantle Cell lymphoma/leukemia.  MRI imaging consistent with
this. 
 * ___ - High dose methotrexate, complicated by acute renal
insufficiency with creatinine peaking at 2.2 felt most likely
from precipitation in the renal tubules.  Creatinine has 
trending
downward, stabilizing at 1.5. Discharged on ___.
 * ___ and ___ - Received Rituxan in divided doses
with mild reaction. 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to his age and renal function; received 2 doses on ___, 1 dose
on ___ and 1 dose on ___.  On Neupogen support during nadir,
required transfusion of red cells and platelets.
 * ___ - C2 RCHOP 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to age and renal function.  High dose MTX on hold with renal
insufficiency.
 * ___ - C3 RCHOP
 * Restaging scan shows interval improvement of lymphoma.  MRI 
of
___ with resolution of previous enhancement.  
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 due
to age and renal function. 
 * ___ - Repeat LP and IT Ara-C given
 * ___ - High dose cytoxan for stem cell mobilization
 * ___ - Started stem cell collections with Neupogen and
Mozibil and collected ~ 5 million CD34 cells/kg over 4 days.
 .
PAST MEDICAL HISTORY:  
- Mantle cell lymphoma/leukemia
- Heterozygous for Factor V Leiden and low Protein S activity of
39%, repeated on ___, now normal 
- Hypertension
- Prostate hypertrophy 
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- Status post appendectomy
- Status post prostate biopsy (incisional)
- Status post repair of deviated nasal septum
.

 
Social History:
___
Family History:
No lymphoma or leukemia in family. Mother had bone cancer, died 
at age ___ with also history of ___. Father died at age 
___ with h/o hypertension, stroke. One brother s/p CABG, stroke 
and ETOH use.
 
Physical Exam:
===============
ADMISSION LABS:
===============
Vitals: ___ 2252 Temp: 97.9 PO BP: 123/84 HR: 69 RR: 18 O2
sat: 95% O2 delivery: Ra  
GENERAL: sitting in bed, appears comfortable, wife at bedside,
NAD
EYES: PERRLA, Anicteric, EOMI
HEENT: OP clear, MMM
NECK:  supple
LUNGS:  CTA b/l, no wheezes/rales/rhonchi, normal RR
CV: RRR no m/r/g, normal distal perfusion, no edema
ABD: soft, NT, ND, normoactive BS, no rebound or guarding
GENITOURINARY: no foley
EXT:  warm, no deformity, normal strength
SKIN: warm, dry, no rash 
NEURO:  AOx3, fluent speech, gross
sensation/strength/coordination intact in all extremities, neg
pronator drift, no cranial nerve deficits
ACCESS: PIV

===============
DISCHARGE LABS:
===============
___ 1229 Temp: 97.9 PO BP: 90/58 L HR: 84 RR: 18 O2 sat: 
94%
O2 delivery: RA 
EYES: PERRLA, Anicteric, EOMI
HEENT: OP clear, MMM
NECK:  Anterior cervical and axillary lymphadenopathy 
LUNGS:  CTA b/l, no wheezes/rales/rhonchi, normal RR
CV: Regular rate, Irregular rhythm, no m/r/g, normal distal
perfusion, no edema
ABD: soft, NT, ND, normoactive BS, no rebound or guarding
GENITOURINARY: no foley
EXT:  warm, no deformity, normal strength
SKIN: warm, dry, scaly plaque in axilla bilaterally, non tender
or pruritic 
NEURO: AOx3, fluent speech, gross 
sensation/strength/coordination
intact in all extremities, neg pronator drift, no cranial nerve
deficits
ACCESS: PIV
 
Pertinent Results:
===============
ADMISSION LABS:
===============
___ 06:40AM BLOOD WBC-4.8 RBC-4.08* Hgb-13.0* Hct-38.5* 
MCV-94 MCH-31.9 MCHC-33.8 RDW-12.7 RDWSD-43.8 Plt ___
___ 06:40AM BLOOD Neuts-59.0 ___ Monos-12.6 Eos-4.8 
Baso-0.6 Im ___ AbsNeut-2.81 AbsLymp-1.08* AbsMono-0.60 
AbsEos-0.23 AbsBaso-0.03
___ 06:40AM BLOOD Glucose-97 UreaN-19 Creat-1.1 Na-141 
K-4.1 Cl-106 HCO3-25 AnGap-10
___ 06:40AM BLOOD ALT-21 AST-22 LD(LDH)-190 AlkPhos-79 
TotBili-0.6
___ 06:40AM BLOOD Calcium-8.7 Phos-2.5* Mg-2.2 UricAcd-5.4
___ 06:40AM BLOOD Vit___-___

=============
MICROBIOLOGY:
=============
__________________________________________________________
___ 4:02 pm CSF;SPINAL FLUID      Source: LP #3. 

                            **FINAL REPORT ___

   GRAM STAIN (Final ___: 
      NO POLYMORPHONUCLEAR LEUKOCYTES SEEN. 
      NO MICROORGANISMS SEEN. 
      This is a concentrated smear made by cytospin method, 
please refer to
      hematology for a quantitative white blood cell count.. 

   FLUID CULTURE (Final ___:    NO GROWTH. 

========
STUDIES:
========
SPECIMEN SUBMITTED: Immunophenotyping-csf
Procedure date     Tissue received     Report Date    Diagnosed 
by 
___ ___. ___ 
Previous biopsies:    ___  Immunophenotyping-bone marrow 
  ___  BONE MARROW, BIOPSY, CORE 
  ___  immunophenotyping - PB 
  ___  immunophenotyping - PB 
(and more) 
DIAGNOSIS: 
FLOW CYTOMETRY REPORT 
FLOW CYTOMETRY IMMUNOPHENOTYPING 
The following tests (antibodies) were performed: Kappa, Lambda, 
FMC-7 and CD antigens 5, 10, 11c, 19, 20, 23, and 45.
RESULTS:
10-color analysis with CD45 vs. side-scatter gating is used to 
evaluate for leukemia/lymphoma.
Only 0.67% of total acquired events are evaluable non-debris 
events.
The viability of the analyzed non-debris events, done by 7-AAD 
is 100.00%.
A focused panel is performed to evaluate B-cells. 
CD45-bright, low side-scatter gated lymphocytes comprise 26.93% 
of total analyzed events.
B cells are scant in number precluding evaluation of 
clonality/further characterization. 
INTERPRETATION
Non-diagnostic study. Cell marker analysis was attempted, but 
was non-diagnostic in this case due to insufficient numbers of 
cells/insufficient amount of tissue for analysis. Correlation 
with clinical and other ancillary findings is recommended. Flow 
cytometry immunophenotyping may not detect all abnormal 
populations due to topography, sampling or artifacts of sample 
preparation. 

SPECIMEN SUBMITTED: Immunophenotyping-bone marrow
Procedure date     Tissue received     Report Date    Diagnosed 
by 
___ ___. ___ 
Previous biopsies:    ___  BONE MARROW, BIOPSY, CORE 
  ___  immunophenotyping - PB 
  ___  immunophenotyping - PB 
  ___  Slides referred for consultation. 
(and more) 
DIAGNOSIS:
FLOW CYTOMETRY REPORT 
FLOW CYTOMETRY IMMUNOPHENOTYPING
The following tests (antibodies) were performed: Kappa, Lambda, 
FMC-7 and CD antigens 5, 10, 11c, 19, 20, 23, and 45.
RESULTS:
10-color analysis with CD45 vs. side-scatter gating is used to 
evaluate for leukemia/lymphoma. 
Approximately 38.53% of total acquired events are evaluable 
non-debris events. 
The viability of the analyzed non-debris events, done by 7-AAD 
is 98.72%.
CD45-bright, low side-scatter gated lymphocytes comprise 13.10% 
of total analyzed events.
A subset (approximately 50%) of B cells demonstrate lambda light 
chain restriction. This population co-expresses pan-B cell 
markers CD19 and CD20 along with CD5 and is negative for CD10, 
CD11c and CD23. The remainder of the B cells detected are 
polyclonal.
A population of hematogones is seen.
INTERPRETATION
Immunophenotypic findings consistent with involvement by mantle 
cell lymphoma. Correlation with clinical, morphologic (see 
separate pathology report ___ and other ancillary 
findings is recommended. Flow cytometry immunophenotyping may 
not detect all abnormal populations due to topography, sampling 
or artifacts of sample preparation.

SPECIMEN: BONE MARROW ASPIRATE AND CORE BIOPSY.
DIAGNOSIS:
NORMOCELLULAR BONE MARROW WITH MATURING TRILINEAGE HEMATOPOIESES 
AND
INVOLVEMENT BY THE PATIENT'S KNOWN MANTLE CELL LYMPHOMA, SEE 
NOTE.
Note: By immunohistochemistry, there are scattered T cells 
immunoreactive for CD3. CD20 highlights multiple paratrabecular 
aggregates of B-cells, which additionally stain with CD5.
By flow cytometry (___), there is a lambda restricted, CD5 
positive B-cell lymphoma consistent with mantle cell lymphoma. A 
BCL1 stain is in progress. MICROSCOPIC DESCRIPTION
Peripheral blood smear: The smears are adequate for evaluation. 
Erythrocytes are slightly decreased in number,
normochromic, normocytic and have no anisopoikilocytosis. The 
white blood cell count is normal. The platelet count is 
decreased. Occasional large and giant platelets are seen. A 100 
cell
differential shows 55% neutrophils, 35% lymphocytes, 5% 
monocytes, 4% eosinophils, and 1% basophils.
Bone marrow aspirate: The aspirate material is adequate for 
evaluation and consists of multiple cellular spicules. The M:E
ratio estimate is 1.4:1 Erythroid precursors are normal in 
number and exhibit predominantly normal
maturation, rare erythroids with irregular nuclear contours are 
seen . Myeloid precursors are normal in number and show 
predominantly normal maturation. Megakaryocytes are normal in 
number;
abnormal forms are seen, including forms that are hypolobated or 
contain disjointed nuclei. A 300 cell differential shows 3% 
blasts, 13% promyelocytes, 15% myelocytes, 8% metamyelocytes, 
17%
bands/neutrophils, 0% eosinophils, 41% erythroids, 3% 
lymphocytes, and 0% plasma cells. ___ 
___
Department of Pathology
___ ___ 2 of 3 
Clot section and biopsy slides:
The core biopsy material is adequate for evaluation. It consists 
of a 1.3 cm long core biopsy composed of cortical bone and 
trabecular marrow with a cellularity of 40-50%. There are 
clusters of
lymphocytes in a para-trabecular organization. Erythroid 
precursors are normal in number and have overall normoblastic 
maturation. Myeloid precursors are normal in number and exhibit 
normal
maturation. Megakaryocytes are mildly increased in number; 
hypolobated forms are seen.

CYTOGENETICS REPORT - Final
SPECIMEN: BONE MARROW
CLINICAL HISTORY: History of mantle cell lymphoma
CYTOGENETICS PROCEDURE: Unstimulated and 3 day 
DSP30/IL2-stimulated cultures for Giemsa-banded chromosome 
analysis.
FINDINGS: An apparently normal 46,XY male chromosome complement 
was observed in 20 mitotic cells examined in detail. Chromosome 
band resolution was 400-450. A karyogram was prepared on
3 cells. CYTOGENETIC DIAGNOSIS: 46,XY[20] Normal male karyotype.
INTERPRETATION/COMMENT: Every metaphase bone marrow cell 
examined appeared to be karyotypically normal. However, FISH 
detected the IGH/CCND1 gene rearrangement in 1% of the 
mononuclear interphase cells examined (see below). These 
findings are consistent with persistence
or recurrence of the patient's known mantle cell lymphoma.
This normal karyotype makes a chromosome abnormality unlikely. 
There is a possibility that low grade mosaicism, a subtle or 
cytogenetically cryptic
chromosome rearrangement, a non-mitotic neoplastic clone, and/or 
copy number neutral loss of heterozygosity would be present and 
go undetected with routine chromosome analysis.
FISH: LOW POSITIVE for IGH/CCND1. 1% of the mononuclear 
interphase bone marrow cells examined had an abnormal probe 
signal pattern consistent with the IGH/CCND1 gene rearrangement 
characteristic of mantle cell lymphoma.
Uncultured cells for fluorescence in situ hybridization (FISH) 
analysis with the ___ Molecular IGH/CCND1 XT dual color dual 
fusion translocation probe set: SpectrumOrange directly labeled 
probe for the CCND1 gene region on ___ and SpectrumGreen 
directly labeled probe for the IGH locus on 14q32. This probe 
combination detects the IGH/CCND1
gene rearrangement brought about by the t(11;14)(q13;q32) 
translocation characteristic of mantle cell lymphoma and seen in 
some plasma cell neoplasms. FINDINGS: A total of 200 interphase 
nuclei were examined with the CCND1 and IGH dual color dual 
fusion probe set
and fluorescence microscopy. 199 cells (99%) had 2 red signals 
and 2 green signals. 2 cells (1%) had ___ yellow ___ 
___-___ Department of Pathology 
Patient: ___ 2 of 2
(red-green fusion) signals, 1 red signal and 1 green signal. 
Normal cut-off values for this probe set include: 86% for a
normal 2 red and 2 green probe signal pattern and 1.5% for a ___ 
yellow (red-green fusion), 1 red and 1 green signal
pattern. ___ ish(CCND1,___)x3(___ con ___
This test was developed and its performance characteristics 
determined by ___ Laboratory. 
It has not been cleared or
approved by the ___ Food ___ Drug Administration (FDA). The FDA 
does not require this test to go through premarket FDA review. 
This test is used for
clinical purposes. It should not be regarded as investigational 
or for research. This laboratory is certified under the Clinical 
Laboratory Improvement Amendments (CLIA) as qualified to perform 
high complexity clinical laboratory testing.
2) FISH: NEGATIVE for DELETION of TP53. No evidence of 
interphase bone marrow cells with deletion of the TP53 gene.
Uncultured cells for fluorescence in situ hybridization (FISH) 
analysis with the ___ Molecular TP53 and CEP17 dual
color probe set: SpectrumOrange directly labeled probe for the 
TP53 gene on 17p13 and SpectrumGreen directly labeled probe for 
the centromeric region of chromosome 17. This probe combination 
detects deletions of the TP53 tumor suppressor gene.
FINDINGS: A total of 200 interphase nuclei were examined with 
the TP53 and CEP17 dual color probe set and fluorescence 
microscopy. 193 cells (91.5%) had 2 red and 2 green signals. 4 
cells (2%) had 1 red signal and 2 green
signals. 3 cells (1.5%) had 1 red signal and 1 green signal. 
Normal cut-off values for this probe set include: 86% for the
normal 2 red and 2 green signal pattern, 8% for a 1 red and 2 
green pattern, and 4% for a 1 red and 1 green pattern.
___ ish(TP53,CEP17)x2[200]

SPECIMEN: LYMPH NODE, RIGHT INGUINAL NODE, CORE NEEDLE BIOPSY.
DIAGNOSIS:
RELAPSED MANTLE CELL LYMPHOMA, SEE NOTE:
Note: Sections of lymph node core biopsies show an effaced 
architecture with a diffuse pattern of abnormal lymphocytes. The 
lymphocytes are primarily medium in size with scant cytoplasm, 
mildly
irregular nuclear contours, coarse and dense chromatin, and 
inconspicuous nucleoli. Occasional mitotic figures are present.
By immunohistochemistry, CD20 highlights the B-cells comprising 
the vast majority of the lymphoid population, while CD3 
highlights scattered T-cells. CD5 and BCL1 are co-expressed in 
the B-cell
population. CD21 and CD23 highlight residual follicular 
dendritic meshworks. BCL2 is diffusely positive. BCL6 and CD10 
are negative. By Ki-67 immunostaining, the proliferation index 
is low with
an overall fraction of 10% which focally increases to 20%.
Overall, the findings are those of a mantle cell lymphoma, 
consistent with the patient's known disease. Correlation with 
clinical, radiographic, cytogenetics (___-___) and flow 
cytometry (see
report ___ findings is recommended.

SPECIMEN SUBMITTED: Immunophenotyping specimen - lymph node

Procedure date     Tissue received     Report Date    Diagnosed 
by 
___ ___. ___ 

Previous biopsies:    ___  BONE MARROW 
  ___  Immunophenotyping-csf 
  ___  Immunophenotyping-bone marrow 
  ___  BONE MARROW, BIOPSY, CORE 
(and more) 
FLOW CYTOMETRY REPORT 
FLOW CYTOMETRY IMMUNOPHENOTYPING
The following tests (antibodies) were performed: Kappa, Lambda, 
FMC-7 and CD antigens 5, 10, 11c, 19, 20, 23 and 45.
RESULTS: 10-color analysis with CD45 vs. side-scatter gating is 
used to evaluate for leukemia/lymphoma. The viability of the 
analyzed non-debris events, done by 7-AAD is 31.9%. A focused 
panel is performed to evaluate B-cells. CD45-bright, low 
side-scatter gated lymphocytes comprise 97.5% of total analyzed 
events. B cells comprise 95% of lymphoid-gated events and 
demonstrate monoclonal lambda light chain restriction. They 
co-express pan-B cell markers CD19 and CD20 along with CD5. They 
do not express any other characteristic antigens including 
FMC-7, CD10, CD11c and CD23. INTERPRETATION: Immunophenotypic 
findings consistent with involvement by mantle cell lymphoma. 
Correlation with clinical, morphologic (see separate pathology 
report ___ and other ancillary findings is recommended. 
Flow cytometry immunophenotyping may not detect all abnormal 
populations due to topography, sampling or artifacts of sample 
preparation.

MR ___ w/ w/out contrast ___:
1. Medial right occipital lobe FLAIR hyperintense leptomeningeal 
enhancement, similar in appearance to examinations of ___ (which had subsequently resolved on follow-up examinations) 
raises concern for recurrent lymphoma thus leptomeningeal 
disease.  This could be further evaluated or confirmed with 
lumbar puncture as clinically indicated. 
2. Unchanged 6 mm focus of tissue isointense to brain 
parenchyma, without 
enhancement, stable since ___, arising from the lateral margin 
of the right middle cerebellar peduncle.  This could represent 
normal brain parenchyma, post treatment change; suggestive of a 
benign entity given stability and lack of enhancement.  This may 
represent a hamartoma. 
3. Interval progression of global parenchymal volume loss and 
now moderate 
changes of chronic white matter microangiopathy since ___. 
4. Solitary nonspecific focus of chronic microhemorrhage, right 
basal ganglia. 
5. Additional findings described above. 

===============
DISCHARGE LABS:
===============
___ 06:20AM BLOOD WBC-4.2 RBC-4.11* Hgb-12.8* Hct-38.8* 
MCV-94 MCH-31.1 MCHC-33.0 RDW-12.9 RDWSD-44.5 Plt Ct-98*
___ 06:20AM BLOOD Neuts-57.6 ___ Monos-11.5 Eos-5.8 
Baso-0.8 Im ___ AbsNeut-2.31 AbsLymp-0.93* AbsMono-0.46 
AbsEos-0.23 AbsBaso-0.03
___ 06:20AM BLOOD Glucose-97 UreaN-28* Creat-1.0 Na-142 
K-4.5 Cl-107 HCO3-23 AnGap-12
___ 06:20AM BLOOD Calcium-8.6 Phos-3.1 Mg-2.1
 
Brief Hospital Course:
==================
SUMMARY STATEMENT:
================== 
___ PMH of Mantle cell lymphoma with CNS involvement
(s/p auto transplant, maintenance rituximab ending ___, 
HTN,
CVA/CRVO, SSS (s/p PPM), pAFib (Eliquis), Convulsive Syncope, 
who
presented from ___ s/p episode of convulsive
syncope, in light of pathologic rib fracture and diffuse
lymphadenopathy seen on imaging s/p LP and BMBx found to have a 
recurrence of mantle cell lymphoma.

==============
ACTIVE ISSUES:
==============
#Convulsive Syncope
Patient has hx of convulsive syncope, of unclear etiology. On 
this current admission, he suffered an episode of convulsive 
syncope following acute pain in right back (possibly due to 
acute rib fracture) which may have precipitated vasovagal spell 
as back to usual self after vomiting, but was seated during 
episode. The patient's wife described the incident as him losing 
consciousness and having twitching of his hands/legs for about 1 
minute. No arrhythmia on Tele, EKG or PPM interrogation and 
troponin negative. No neurologic exam findings to suggest 
stroke. Seizure possible given urinary incontinence, but patient 
and wife deny post ictal state or tongue biting and EEG without 
epileptic activity. CTH without new bleed or mass, although 
there is a new lacunar infarct not seen on prior CTH. Had 
orthostatic vital signs ___ AM although asymptomatic and given 
fluid bolus, but this does not seem to be the culprit of his 
syncopal episode. He had an MRI that showed a medial right 
occipital lobe FLAIR hyperintense leptomeningeal enhancement, 
similar in appearance to examinations of ___ (which had 
subsequently resolved on follow-up examinations). This likely 
does not represent new CNS lymphoma.

#Mantle Cell Lymphoma Recurrence
#Diffuse Lymphadenopathy seen on CT Chest
Diffuse lymphadenopathy on exam and CT highly suspicious for
malignancy given concurrent pathologic rib fracture and diffuse
lymphadepathy. Upon presentation denied B symptoms and no 
signs/symptoms of infection. CTH without CNS involvement and MRI 
with right occipital FLAIR hyperintense enhancement, but per 
neuro oncology likely does not represent new CNS lymphoma. BM 
and LN biopsy with mantle cell lymphoma and LP with elevated 
protein but without malignant cells. Will set patient up with 
follow up for PET scan and treatment for his mantle cell 
lymphoma in ___ days from discharge. He will continue on his 
acyclovir ppx.

#Acute Pathologic Rib Fracture
Patient described acute right back pain which precipitated above
event and may have represented acute fracture, although short
duration of pain and the fact that it is completely resolved as
well as described location is not consistent with a new rib
fracture. Fortunately, he is now asymptomatic and did not 
require analgesia while in house.

===============
CHRONIC ISSUES:
===============
#Afib: On apixaban at home. Was on heparin gtt for procedures 
and
now back on home apixaban.

#Hx of B12 deficiency
Has on and off again use of B12. B12 wnl on admission.

#SSS s/p PPM
#hx of CVA/CRVO
#hx of pAFIB
#HLD
#HTN
No arrhythmia on EKG on PPM interrogation and troponin negative
so tele discontinued. His statin was discontinued initially, but 
re-started on discharge. He was also continued on his home 
losartan. 

#Lacunar infarct seen on CT: Appears new from last scan, no new 
sx. MRI without evidence of new infarct. 

====================
TRANSITIONAL ISSUES:
====================
[] Patient should have PET scan prior to therapy
[] Will follow up with outpatient oncology to re-establish care 
and start treatment
[] Of note, patient and family would like care close to home 

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Tamsulosin 0.4 mg PO QHS 
2. Atorvastatin 80 mg PO QPM 
3. Acyclovir 400 mg PO Q12H 
4. Albuterol Inhaler 2 PUFF IH Q6H:PRN sob 
5. Apixaban 5 mg PO BID 
6. FoLIC Acid 1 mg PO DAILY 
7. Losartan Potassium 50 mg PO DAILY 
8. Cyanocobalamin 1000 mcg PO EVERY OTHER DAY 

 
Discharge Medications:
1.  Clotrimazole Cream 1 Appl TP BID Duration: 1 Week  
2.  Acyclovir 400 mg PO Q12H  
3.  Albuterol Inhaler 2 PUFF IH Q6H:PRN sob  
4.  Apixaban 5 mg PO BID  
5.  Atorvastatin 80 mg PO QPM  
6.  Cyanocobalamin 1000 mcg PO EVERY OTHER DAY  
7.  FoLIC Acid 1 mg PO DAILY  
8.  Losartan Potassium 50 mg PO DAILY  
9.  Tamsulosin 0.4 mg PO QHS  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Primary Diagnosis:
==================
Mantle Cell Lymphoma Recurrence
Syncope of unknown etiology

Secondary Diagnosis:
====================
Atrial fibrillation
SSS
Lacunar infarct on CT
Pathologic rib fracture
HTN
HLD

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure taking care of you at ___!

WHY WAS I ADMITTED TO THE HOSPITAL?
- You were admitted because you had an episode where you lost 
consciousness and were found to have enlarged lymph nodes at 
___ with concern for a recurrence of your 
lymphoma

WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?
- You had an EEG that did not show seizure activity and your 
pacemaker did not show any arrhythmias that would explain your 
loss of consciousness
- Our radiologists reviewed the CT scan of your chest from ___ 
___ and you had a CT scan of your abdomen and pelvis 
that showed enlarged lymph nodes
- You had a bone marrow and lymph node biopsy that showed mantle 
cell lymphoma (the same lymphoma you had originally)
- You had a lumbar puncture to look at the fluid surrounding 
your brain and spine that did not show signs of lymphoma in the 
brain
- You had an MRI of your brain that showed a change in the back 
portion of your brain that was present ___ years ago. This likely 
does not represent lymphoma of the brain. 

WHAT SHOULD I DO WHEN I GO HOME?
- Please continue taking your medications as prescribed and go 
to all of your follow up appointments
- You should have an outpatient PET scan
- Our team will set you up with an oncologist; you can follow up 
with this person as an outpatient and for the start of your 
treatment

We wish you the best,

Your ___ care team
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-16 | hadm_id=22156647

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
Admission for second cycle of high dose Ara-C treatment for 
mantle cell lymphoma/leukemia with CNS involvement
 
Major Surgical or Invasive Procedure:
None 

 
History of Present Illness:
___ male with mantle cell leukemia/lymphoma with CNS 
involvement presenting for admission for second cycle of high 
dose Ara-C treatment.  Pt reports feeling well.  He reports 
having stubbed his right great toe and now has some erythema 
there.  He has been taking keflex for the toe.  He also noted a 
rash on his right elbow/forearm today that is now resolving.  

Previously, he has had high dose Ara-C and two cycles of RCHOP.  
Initially, it was planned that he receive methotrexate in 
between cycles but he developed ___ and methotrexate has been 
held.   

Review of Systems:  
(+) Per HPI  
(-) Denies fever, chills, night sweats, recent weight loss or 
gain. Denies blurry vision, diplopia, loss of vision, 
photophobia. Denies headache, sinus tenderness, rhinorrhea or 
congestion. Denies chest pain or tightness, palpitations, lower 
extremity edema. Denies cough, shortness of breath, or wheezes. 
Denies nausea, vomiting, diarrhea, constipation, abdominal pain. 
All other systems negative.  
 
Past Medical History:
PAST ONCOLOGIC HISTORY:  
- Mantel Cell Lymphoma, recently diagnosed 2 weeks ago, with new 
CNS involvement, s/p R-CHOP (Cycle 1, Day 1 on ___, Day 2 on 
___

PAST MEDICAL HISTORY:  
- Hypertension
- Prostate hypertrophy
- Chronic lymphocytic leukemia  
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- s/p Appendectomy
- s/p Prostate biopsy (incisional)
- s/p Repair of deviated nasal septum

 
Social History:
___
Family History:
CABG, hyperlipidemia, mental retardation.

 
Physical Exam:
Admission:
Vitals - 98.0  113/62  75  18  95%RA   
GENERAL: NAD  
HEENT: AT/NC, EOMI, PERRLA, anicteric sclera, pink conjunctiva, 
patent nares, MMM, good dentition, nontender supple neck, no 
LAD, no JVD  
CARDIAC: RRR, S1/S2, no murmers, gallops, or rubs
LUNG: CTAB, no wheezes, rales, rhonchi, breathing comfortably 
without use of accessory muscles
ABDOMEN: nondistended, nontender in all quadrants, no 
rebound/guarding, no hepatosplenomegaly  
EXTREMITIES: moving all extremities well, no cyanosis, clubbing 
or edema, no obvious deformities, mild erythema with no purulent 
drainage at right great toenail edge
PULSES: 2+ DP pulses bilaterally  
NEURO: CN II-XII intact, cerebellar function (finger to nose, 
heel to shin) intact 
SKIN: warm and well perfused, no excoriations or lesions, no 
rashes

Discharge:
Vitals - Patient was afebrile, normotensive, non-tachycardic, 
non-tachypneic, O2 sat >95% on room air  
GENERAL: NAD  
HEENT: AT/NC, EOMI, PERRLA, anicteric sclera, pink conjunctiva, 
patent nares, MMM, good dentition, nontender supple neck, no 
LAD, no JVD  
CARDIAC: RRR, S1/S2, no murmers, gallops, or rubs
LUNG: CTAB, no wheezes, rales, rhonchi, breathing comfortably 
without use of accessory muscles
ABDOMEN: nondistended, nontender in all quadrants, no 
rebound/guarding, no hepatosplenomegaly  
EXTREMITIES: moving all extremities well, no cyanosis, clubbing 
or edema, no obvious deformities, right great toenail trimmed 
without erythema or exudates
PULSES: 2+ DP pulses bilaterally  
NEURO: CN II-XII intact, cerebellar function (finger to nose, 
heel to shin) intact 
SKIN: warm and well perfused, no excoriations or lesions, no 
rashes
 
Pertinent Results:
Admission Labs:
___ 10:58AM BLOOD WBC-6.8# RBC-3.26* Hgb-10.0* Hct-29.7* 
MCV-91 MCH-30.6 MCHC-33.5 RDW-19.0* Plt ___
___ 10:58AM BLOOD Neuts-60 Bands-15* Lymphs-14* Monos-7 
Eos-0 Baso-0 Atyps-3* Metas-1* Myelos-0
___ 10:58AM BLOOD Hypochr-NORMAL Anisocy-2+ Poiklo-NORMAL 
Macrocy-1+ Microcy-NORMAL Polychr-1+ Ovalocy-1+
___ 10:58AM BLOOD UreaN-15 Creat-1.4* Na-139 K-4.0 Cl-104 
HCO3-26 AnGap-13
___ 10:58AM BLOOD ALT-23 AST-27 LD(LDH)-285* AlkPhos-52 
TotBili-0.4
___ 10:58AM BLOOD Albumin-4.4 Calcium-9.5 Mg-1.9 
UricAcd-6.2

Discharge Labs:
___ 08:15AM BLOOD WBC-4.6 RBC-2.81* Hgb-8.6* Hct-25.6* 
MCV-91 MCH-30.5 MCHC-33.4 RDW-18.4* Plt ___
___ 08:15AM BLOOD Glucose-113* UreaN-21* Creat-1.2 Na-141 
K-4.0 Cl-108 HCO3-23 AnGap-14
___ 08:15AM BLOOD ALT-18 AST-22 AlkPhos-45 TotBili-0.2
___ 08:15AM BLOOD Calcium-8.8 Phos-4.3 Mg-2.___rief Course:
Mr. ___ is a ___ male with mantle cell 
leukemia/lymphoma with CNS involvement presenting for admission 
for second cycle of high dose Ara-C treatment.

Active Issues:
# Mantle Cell Lymphoma: Patient received his second cycle of 
high dose Ara-C, dose adjusted for renal function. He tolerated 
the treatment well without complications. He had no signs of 
cerebellar or renal toxicity, fevers, nausea, or vomiting. His 
cell counts remained stable and he did not require Neupogen. He 
will continue to use prednisolone eye drops until 48 hours after 
his last Ara-C dose and continue Bactrim for prophylaxis.  

# Ingrown Toenail: Patient's right great toe was noted to have 
erythema near the edge of the toenail. It was likely ingrown 
toenail. Podiatry trimmed and cleaned out toenail. He had been 
taking Keflex prior to admission for possible infection, and 
will continue taking this antibiotic to complete a 7-day 
treatment course.

Inactive Issues:
# Acute kidney injury: Patient's creatinine peaked at 2.2 in 
___ after initiating methotrexate. It has come down and 
stabilized at 1.4-1.5 since then. We monitored the patient's 
renal function carefully while on high dose Ara-C and it is 
currently stable.

# Retinal vein occlusion: Patient has a history of retinal vein 
occlusion in the setting of CNS involvement of his mantle cell 
lyphoma/leukemia with choroidal deposits. He is s/p Avastin 
injection in ___. His vision is currently stable and the 
patient has no complaints. He will follow up with his outpatient 
ophthalmologist.

Transitions of Care:
1. Code Status: Full  
2. Contact: Wife ___ 
3. ___ Studies: None
4. Medication Changes: 
-Continue taking Keflex until ___ to complete a 7 day course
-Prednisolone eyedrops three times a day in both eyes until 48 
hours after your last chemotherapy dose (until ___
5. Follow up: 
-Dr. ___ (Oncology)
 
Medications on Admission:
Preadmission medications listed are correct and complete.  
Information was obtained from PatientwebOMR.
1. Allopurinol ___ mg PO DAILY 
2. Lorazepam 0.5-1 mg PO Q8H:PRN anxiety or nausea 
3. Omeprazole 20 mg PO DAILY 
4. Ondansetron 8 mg PO Q8H:PRN nausea 
5. Sulfameth/Trimethoprim DS 1 TAB PO QMOWEFR 
6. Biotene Dry Mouth *NF* (lactoperoxi-gluc oxid-pot thio)    
Mucous Membrane BID 
7. Clotrimazole Cream 1 Appl TP BID 
8. Cephalexin 500 mg PO Q6H 

 
Discharge Medications:
1. Allopurinol ___ mg PO DAILY 
2. Ondansetron 8 mg PO Q8H:PRN nausea 
3. Sulfameth/Trimethoprim DS 1 TAB PO QMOWEFR 
4. Biotene Dry Mouth *NF* (lactoperoxi-gluc oxid-pot thio) 0  cc 
MUCOUS MEMBRANE BID 
5. Clotrimazole Cream 1 Appl TP BID 
6. Cephalexin 500 mg PO Q6H 
7. PrednisoLONE Acetate 1% Ophth. Susp. 1 DROP BOTH EYES TID 
continue 48 hours after last dose of cytarabne 
RX *prednisolone acetate 1 % 1 drop eyes three times a day Disp 
#*1 Vial Refills:*0

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Primary: 
Mantle cell lymphoma

Secondary: 
Ingrown toenail

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
It was a pleasure taking care of you in the hospital.  You were 
admitted for your second cycle of chemotherapy with high dose 
Ara-C.  You tolerated the chemotherapy well and you were 
discharged home.  

While you were in the hospital, you were seen by podiatry for an 
ingrown toenail that was trimmed.  

You should continue taking the antibiotic (cephalexin 500mg 
every 6 hours) until ___ to complete a 7 day course

You should use the prednisolone eyedrops three times a day in 
both eyes until 48 hours after your last chemotherapy dose. Your 
last chemotherapy was on ___ so you should continue the 
drops until ___.

Please continue your other medications as you were doing. 
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-19 | hadm_id=22547021

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
___ Complaint:
Elective admission for autologous stem cell transplant
 
Major Surgical or Invasive Procedure:
- Central line placement
- Autologous stem cell transplant 

 
History of Present Illness:
Mr. ___ is a ___ with mantle cell lymphoma/leukemia with 
central nervous system involvement who is admitted for 
autologous stem cell transplantation. He feels well without 
concerns. He acknowledges poor oral intake, but denies 
nausea/vomiting or diarrhea.

 
Past Medical History:
ONCOLOGIC HISTORY:
 * ___ - C1 CHOP
 * ___ - Admitted urgently due to choroidal cellular
infiltrate in the left eye concerning for CNS involvement from
his Mantle Cell lymphoma/leukemia.  MRI imaging consistent with
this. 
 * ___ - High dose methotrexate, complicated by acute renal
insufficiency with creatinine peaking at 2.2 felt most likely
from precipitation in the renal tubules.  Creatinine has 
trending
downward, stabilizing at 1.5. Discharged on ___.
 * ___ and ___ - Received Rituxan in divided doses
with mild reaction. 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to his age and renal function; received 2 doses on ___, 1 dose
on ___ and 1 dose on ___.  On Neupogen support during nadir,
required transfusion of red cells and platelets.
 * ___ - C2 RCHOP 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to age and renal function.  High dose MTX on hold with renal
insufficiency.
 * ___ - C3 RCHOP
 * Restaging scan shows interval improvement of lymphoma.  MRI 
of
head with resolution of previous enhancement.  
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 due
to age and renal function. 
 * ___ - Repeat LP and IT Ara-C given
 * ___ - High dose cytoxan for stem cell mobilization
 * ___ - Started stem cell collections with Neupogen and
Mozibil and collected ~ 5 million CD34 cells/kg over 4 days.
 .
PAST MEDICAL HISTORY:  
- Mantle cell lymphoma/leukemia
- Heterozygous for Factor V Leiden and low Protein S activity of
39%, repeated on ___, now normal 
- Hypertension
- Prostate hypertrophy 
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- Status post appendectomy
- Status post prostate biopsy (incisional)
- Status post repair of deviated nasal septum
.

 
Social History:
___
Family History:
No lymphoma or leukemia in family. Mother had bone cancer, died 
at age ___ with also history of ___. Father died at age 
___ with h/o hypertension, stroke. One brother s/p CABG, stroke 
and ETOH use.
 
Physical Exam:
On admission:
VS: T 98.1  bp 131/70  HR 79  RR 18  SaO2 96RA
GEN: NAD, awake, alert  
HEENT: EOMI, sclera anicteric, conjunctivae clear, OP moist and 
without lesion
NECK: Supple  
CV: Reg rate, normal S1, S2. No m/r/g.   
CHEST: Resp unlabored, no accessory muscle use. CTAB, no 
crackles, wheezes or rhonchi.  Port on left chest is accessed 
and non-tender
ABD: Soft, NT, ND, bowel sounds present
MSK: normal muscle tone and bulk
EXT: No c/c, normal perfusion
SKIN: warm skin, ___ non-tender nodule on back 1.5cm in largest 
diameter
NEURO: oriented x 3, normal attention, no focal deficits, intact 
sensation to light touch
PSYCH: appropriate

At discharge:
VS: 98.2/99.5 96/58 90 18 98%RA 
GEN: NAD, awake, alert  
HEENT: EOMI, sclerae anicteric, conjunctivae clear, OP clear, 
blue filling exposed on right upper molar
NECK: Supple  
CV: RRR, normal S1, S2. No m/r/g.  
CHEST: Resp unlabored, no accessory muscle use. CTAB, no 
crackles, wheezes or rhonchi. Port on left chest is accessed and 
non-tender  
ABD: Soft, NT, ND, bowel sounds present  
MSK: normal muscle tone and bulk  
EXT: No c/c, normal perfusion, petechia overlying anterior 
distal shin  
SKIN: warm skin, small non-tender nodule on back 1.5cm in 
largest diameter, diffuse erythematous, macular, confluent, non 
pruritic rash on trunc
NEURO: oriented x 3, normal attention, no focal deficits, intact 
sensation to light touch  
PSYCH: appropriate  
 
 
Pertinent Results:
On admission:
___ 05:47PM   GLUCOSE-107* UREA N-27* CREAT-1.2 SODIUM-142 
POTASSIUM-3.9 CHLORIDE-107 TOTAL CO2-26 ANION GAP-13
___ 05:47PM   CALCIUM-8.6 PHOSPHATE-3.9 MAGNESIUM-2.2
___ 05:42PM URINE  OSMOLAL-214
___ 05:31PM URINE  COLOR-Straw APPEAR-Clear SP ___
___ 05:31PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG 
GLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.5 
LEUK-TR
___ 05:31PM URINE  RBC-<1 WBC-3 BACTERIA-NONE YEAST-NONE 
EPI-0
___ 10:40AM   GLUCOSE-113*
___ 10:40AM   UREA N-30* CREAT-1.5* SODIUM-143 
POTASSIUM-4.5 CHLORIDE-104 TOTAL CO2-27 ANION GAP-17
___ 10:40AM   ALT(SGPT)-21 AST(SGOT)-22 LD(LDH)-162 ALK 
PHOS-90 TOT BILI-0.4 DIR BILI-0.1 INDIR BIL-0.3
___ 10:40AM   TOT PROT-7.0 ALBUMIN-4.7 GLOBULIN-2.3 
CALCIUM-9.7 PHOSPHATE-4.1 MAGNESIUM-2.4 URIC ACID-6.4
___ 10:40AM   WBC-3.6*# RBC-3.26*# HGB-11.3*# HCT-32.4*# 
MCV-99* MCH-34.7* MCHC-34.9 RDW-17.2*
___ 10:40AM   NEUTS-83* BANDS-3 LYMPHS-8* MONOS-5 EOS-0 
BASOS-0 ___ MYELOS-1*
___ 10:40AM   HYPOCHROM-NORMAL ANISOCYT-1+ POIKILOCY-NORMAL 
MACROCYT-OCCASIONAL MICROCYT-NORMAL POLYCHROM-NORMAL
___ 10:40AM   PLT SMR-NORMAL PLT COUNT-191#
___ 10:40AM   ___ PTT-31.3 ___
 
At discharge: 
___ 07:00AM BLOOD WBC-8.7 RBC-3.10* Hgb-10.4* Hct-29.6* 
MCV-95 MCH-33.6* MCHC-35.2* RDW-17.1* Plt Ct-34*
___ 07:00AM BLOOD Neuts-87* Bands-3 Lymphs-3* Monos-6 Eos-0 
Baso-0 Atyps-1* ___ Myelos-0
___ 07:00AM BLOOD Hypochr-1+ Anisocy-1+ Poiklo-1+ 
Macrocy-1+ Microcy-NORMAL Polychr-NORMAL Ovalocy-1+
___ 07:00AM BLOOD ___ PTT-32.6 ___
___ 07:00AM BLOOD Glucose-103* UreaN-16 Creat-1.0 Na-138 
K-4.4 Cl-102 HCO3-27 AnGap-13
___ 07:00AM BLOOD ALT-24 AST-29 LD(LDH)-232 AlkPhos-93 
TotBili-0.6
___ 07:00AM BLOOD Calcium-8.6 Phos-3.2 Mg-2.1
 
Pending: 
___ 04:35PM BLOOD PARVOVIRUS B19 DNA-PND
___ Immunology (CMV) CMV Viral Load-PENDING 
INPATIENT 
___ CATHETER TIP-IV WOUND CULTURE-FINAL 
INPATIENT 
___ BLOOD CULTURE Blood Culture, Routine-PENDING 
INPATIENT 
___ BLOOD CULTURE Blood Culture, Routine-PENDING 
INPATIENT 

Microbiology:
C. difficile (___): Negative
CMV (___): Negative
___ CATHETER TIP-IV WOUND CULTURE-FINAL negative
___ BLOOD CULTURE Blood Culture, Routine-FINAL 
negative
___ BLOOD CULTURE Blood Culture, Routine-FINAL 
negative 
___ BLOOD CULTURE Blood Culture, Routine-FINAL 
negative  
___ BLOOD CULTURE Blood Culture, Routine-FINAL 
negative  
 
Studies:
___ CXR (PA and lateral):  Heart size is top normal, 
stable.  Mediastinum is unremarkable.  In the right lower lung, 
there was a questionable opacity seen on the portable radiograph 
but no evidence is currently seen with abnormality most likely 
reflecting summation of vascular shadows.  If patient's symptoms 
persist, assessment with a chest CT to exclude the possibility 
of radiographically occult process might be considered. Right 
central venous line tip is at the level of superior SVC. 
 
___ CXR: Left lung is clear.  Infrahilar opacity in the 
right lung could be  atelectasis, but in any case a bedside 
chest radiographs should not be relied  upon to exclude 
pneumonia in a patient under these circumstances.  Heart size  
top normal.  No pulmonary edema and no appreciable pleural 
effusion.  Right subclavian line ends in the upper-to-mid SVC. 
 
FDG tumor imaging from ___ shows  
1. No new FDG disease or lymphadenopathy.  
2. Unchanged regional tracer uptake in the gastric cardia,  
possibly physiologic versus inflammatory in nature.  
3. Multinodular thyroid with increased FDG uptake in a  
left-sided nodule compared to prior PET-CT.  
  
ECHOCARDIOGRAM from ___ shows LVEF of > 60%.  
 
PFT's from ___ with FVC 108%, FEV1 104%, and DLCO 89%.
 
Brief Hospital Course:
Mr. ___ is a ___ with with mantle cell lymphoma/leukemia with 
central nervous system involvement admitted for autologous stem 
cell transplantation on BEAM regimen. 
 
<< Active Issues:
# Mantle Cell Lymphoma: He underwent autologous stem cell 
transplantation on BEAM regimen, with home Bactrim and acyclovir 
prophylaxis held on admission and subsequently resumed per 
protocol. He received filgrastim treatment through his nadir, as 
well as supportive transfusions with pRBC and platelets. In the 
setting of poor appetite and oral mucositis, total parenteral 
nutrition was initiated. As his mucositis improved, he was 
transitioned back to PO and was tolerating comfortably. 
 
# Neutropenic fever: Spiked to 102.4 overnight ___ and to 
100.7 over the next day, but has remained afebrile until ___ 
AM when he spiked to 100.5. This resolved without intervention. 
Started on emperic vancomycin / cefepime, which was discontinued 
(___). Infectious workup unrevealing.  Line site was not 
erythematous or nontender, but was most likely source of fever 
so was pulled on ___ and tip sent for culture, which was 
negative. CXR from ___ without evidence of pneumonia.  Blood 
and urine cultures negative. 
   
# Acute kidney injury: Creatinine of 1.5 on admission, versus 
recent baseline of 1, was likely prerenal in etiology in the 
setting of poor oral intake, with improvement to ___ 
throughout the rest of admission following IV fluid 
administration.
 
# Presyncope: He experienced lightheadedness on minimal 
ambulation within his room on ___, likely due to orthostatic 
hypotension in the setting of poor oral intake and anemia, with 
symptomatic improvement following supportive pRBC transfusion. 
Noncontrast head CT was negative for acute intracranial process.
  
# Afib with RVR: ___ at 10AM pt in afib with RVR to 120s. SBP 
stable in 130s and patient asymptomatic. No history of afib, 
unclear etiology, but possibly related to infection given fever 
or anemia given slowly downtrending hct. Resolved ___ after 
approximately 7 hours.  TSH normal. CXR PA/Lat without 
pneumonia.  He was started on metoprolol which he continued for 
several days, but discontinued prior to discharge.
 
# Retinal vein occlusion: Felt likely in setting of CNS 
involvement and choroidal deposits noted. S/p Avastin injections 
on ___, and ___ with laser treatment. Also with 
h/o heterozygous Factor V Leiden and low Protein S activity, 
with repeat Protein S normal. 
 
<< Transitional Issues:
-Code status: Full.
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Acyclovir 400 mg PO Q12H 
2. Allopurinol ___ mg PO DAILY 
3. Lorazepam 0.5-1 mg PO Q8H:PRN insomnia or nausea 
4. Omeprazole 20 mg PO DAILY PRN indigestion 
5. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN bone pain 
6. Sulfameth/Trimethoprim DS 1 TAB PO MON, WEDS, FRI 
7. Dexamethasone 8 mg PO Q12H Duration: 2 Days 
8. lactoperoxi-gluc oxid-pot thio *NF* 15 ml Mucous Membrane BID 

9. Ondansetron 8 mg PO Q8H:PRN nausea 

 
Discharge Medications:
1. Acyclovir 400 mg PO Q12H 
RX *acyclovir 400 mg 1 tablet(s) by mouth every eight (8) hours 
Disp #*45 Tablet Refills:*0
2. Lorazepam 0.5-1 mg PO Q8H:PRN insomnia or nausea 
RX *lorazepam [Ativan] 0.5 mg ___ tabs by mouth twice a day Disp 
#*15 Tablet Refills:*0
3. Omeprazole 20 mg PO DAILY PRN indigestion 
RX *omeprazole 20 mg 1 capsule(s) by mouth daily Disp #*15 
Capsule Refills:*0
4. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN bone pain 
RX *oxycodone 5 mg ___ tablet(s) by mouth every four (4) hours 
Disp #*30 Tablet Refills:*0
5. Ondansetron 8 mg PO Q8H:PRN nausea 
RX *ondansetron 8 mg 1 tablet(s) by mouth every eight (8) hours 
Disp #*15 Tablet Refills:*0

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
- Mantle cell lymphoma admitted for autologous stem cell 
transplant 
- Febrile neutropenia
- Thrombocytopenia requiring multiple platelet transfusions 
- Anemia requiring multiple blood transfusions
- Epistaxis
- Hyponatremia 
- Acute kidney injury

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure taking care of you at the ___.  You were 
admitted for a stem cell transplant with your on cells 
(autologous  transplant).  
 
You had a fever while your cell counts were low, so you were on 
antibiotics for several days and these have since been 
discontinued. You required several platelet and blood 
transfusions while you were here and you had a couple episodes 
of nose bleeding due to your low platelets.  Your counts 
recovered well and you began to more like your baseline, so you 
were discharged to the ___ with close follow up. 
 
 
While you were having a fever and had low blood counts, your 
heart went into a rhythm called atrial fibrillation. This 
resolved after several hours, but we had started you on a heart 
medicine called metoprolol to help control the rate.  You should 
follow up with your PCP to determine whether you need to 
continue taking this medication.  
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-14 | hadm_id=23833799

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
scheduled admission for chemotherapy
 
Major Surgical or Invasive Procedure:
lumbar puncture
intraocular injection

 
History of Present Illness:
Mr. ___ is a ___ recently diagnosed with mantel cell lymphoma 
with CNS involvement s/p C1D11 CHOP who is presenting for high 
dose MTX for possible CNS involevement.

The patient was found to have elevated white count in ___ 
and was briefly lost to follow up while trying to establish care 
with a new PCP and was recently seen a few weeks ago when he was 
noted to have white count of 35. Following his incidental 
leukocytosis, he established care with Dr. ___ in ___ 
in ___.  Bone marrow biopsy showed many medium sized 
lymphocytes, no smudge cells, some cells (~10%) with more open 
chromatin and nucleoli.  The cells were found to be CD ___ + 
with CD1 translocation.  The patient was diagnosed with Mantel 
Cell Lymphoma.

Around the same time, the patient noticed a small amount of 
blurry vision in his left eye.  He saw an ophthalmologist and 
was then referred to Dr. ___ at the ___ 
where he was found to have distal branch occlusion of a retinal 
vein with subretinal infiltrates and macular edema.  Given this 
eye presentation, there is concern that the lymphoma is now 
involving the patient's choroid. 

The patient was referred to Dr. ___ on ___ for R-CHOP 
(Cycle 1, Day 1) and received treatment on ___ and ___ without 
incident.  The patient does report improvement in his blurry 
vision following CHOP. The patient tolerated CHOP well, does 
report feeling less "sharp," but denies any confusion.  Also 
reports feeling constipated s/p CHOP.

Currently, the patient reports he feels well and denies 
complaints including pain. Of note, over the last few months, 
the patient denies any weight loss, fatigue or night sweats.  
However, as per report, the patient's wife reports that he has 
been more tired than usual.  Denies any abdominal pain.  

 
Past Medical History:
PAST ONCOLOGIC HISTORY:  
- Mantel Cell Lymphoma, recently diagnosed 2 weeks ago, with new 
CNS involvement, s/p R-CHOP (Cycle 1, Day 1 on ___, Day 2 on 
___

PAST MEDICAL HISTORY:  
- Hypertension
- Prostate hypertrophy
- Chronic lymphocytic leukemia  
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- s/p Appendectomy
- s/p Prostate biopsy (incisional)
- s/p Repair of deviated nasal septum

 
Social History:
___
Family History:
CABG, hyperlipidemia, mental retardation.

 
Physical Exam:
Admission PE:
Vitals:  98.7   128/74   79   16   97%RA  Wt 201.8 lbs, 67"
General: pleasant, well appearing gentleman, looks younger than 
stated age, joking  
HEENT: EOMI, moist mucous membranes
CARDIAC: RRR, S1/S2, no murmurs/rubs/gallops appreciated 
LUNG: CTAB, no wheezes/rhonchi/crackles noted  
ABDOMEN: soft, nontender, nondistended, +BS
EXT: warm, well perfused, no ___ edema, 2+ DP pulses
Neuro: normal gait, muscle strength grossly intact 

Discharge PE:
VS: Tm 98.5 97.9  124/72 (118-148/66-92) 74 (71-81) 20 97RA
8h: UOP 1225 / 120PO + 465 IV 
24h: UOP 3080 / 1220PO + 1082
General: Pleasant, well appearing gentleman, looks younger than 
stated age, laying comfortably in bed
HEENT: EOMI, PERRL, moist mucous membranes, L eye outer sclera 
bloody and red
CARDIAC: RRR, S1/S2, no murmurs/rubs/gallops
LUNG: CTAB, no wheezes/rhonchi/crackles
ABDOMEN: Soft, nontender, nondistended, +BS
EXT: Warm, well perfused, no ___ edema
Neuro: Grossly normal

 
Pertinent Results:
Admission labs:

___ 05:20PM BLOOD WBC-13.4*# RBC-3.51* Hgb-10.7* Hct-31.1* 
MCV-89 MCH-30.6 MCHC-34.5 RDW-14.7 Plt ___
___ 05:20PM BLOOD Neuts-10* Bands-0 Lymphs-88* Monos-0 
Eos-0 Baso-0 Atyps-2* ___ Myelos-0
___ 05:20PM BLOOD Glucose-82 UreaN-20 Creat-1.2 Na-137 
K-4.5 Cl-103 HCO3-27 AnGap-12
___ 05:20PM BLOOD ALT-19 AST-25 LD(___)-139 AlkPhos-57 
TotBili-0.2
___ 05:20PM BLOOD Calcium-9.0 Phos-3.4 Mg-2.2 UricAcd-4.6\

Discharge labs:
___ 07:50AM BLOOD WBC-9.5 RBC-3.25* Hgb-9.6* Hct-28.4* 
MCV-87 MCH-29.6 MCHC-33.9 RDW-15.0 Plt ___
___ 07:50AM BLOOD Neuts-9.2* Lymphs-88.9* Monos-0.8* 
Eos-0.3 Baso-0.8
___ 07:50AM BLOOD Glucose-99 UreaN-23* Creat-1.9* Na-138 
K-3.5 Cl-101 HCO3-32 AnGap-9
___ 07:50AM BLOOD ALT-51* AST-42* LD(___)-215 AlkPhos-48 
TotBili-0.6
___ 07:50AM BLOOD Albumin-3.7 Calcium-8.4 Phos-2.5* Mg-2.3

MRI head:
IMPRESSION: 
1.  Focal right occipital lobar sulcal FLAIR-hyperintensity 
concerning for subarachnoid hemorrhage.  Note that though the 
FLAIR sequence was obtained post-contrast administration and 
that, therefore, the sulcal hyperintensity could represent 
leptomeningeal enhancement, this is less likely, given the lack 
of convincing enhancement on post contrast T1-weighted SE and 
MP-RAGE sequences. In the absence of history of trauma, the 
possible etiologies include, but are not limited to, 
leptomeningeal amyloidosis and reversible cerebral 
vasoconstriction syndrome (RCVS, or ___ syndrome). 
2.  Chronic left caudate head infarction with ex vacuo 
dilatation of the left lateral ventricle. 

repeat MRI head:
IMPRESSION: 
1.  Previous FLAIR-signal abnormality is redemonstrated.  It is 
seen only on the post-contrast FLAIR images and is consistent 
with leptomeningeal 
enhancement, concerning for focal lymphomatous spread. This 
finding should be closely correlated with clinical and 
laboratory data, including results of most recent CSF cytology 
and flow-cytometry. 
2.  Sequelae of chronic small vessel ischemic disease. 
3.  Chronic left caudate head infarct with ex vacuo dilatation 
of the frontal horn of left lateral ventricle, re-demonstrated. 

CT head:
IMPRESSION: 
1.  Focal right occipital polar subarachnoid hemorrhage is seen 
better on the concurrent enhanced MR study. 
2.  Old infarct of the left caudate head, with cystic 
encephalomalacia and volume loss. 

 
Brief Hospital Course:
Mr. ___ is ___ with newly diagnosed mantle cell lymphoma s/p  
C1 CHOP who is presenting for HD MTX treatment in the setting of 
possible CNS involvement of lymphoma. 

# Mantle Cell Lymphoma:  The patient has newly diagnosed mantel 
cell lymphoma and is s/p C1 R-CHOP.  He has had recent retinal 
vein occlusion and is currently being worked up by optho at 
___.  Based on exams at ___, there is e/o subretinal 
deposits that are concerning for CNS involvement of the 
patient's lymphoma.  The patient had MRI and CT scan of the 
brain which initially did not show clear e/o lymphoma 
involvement, and instead showed evidence of subarachnoid 
hemorrhage (see below).  However, on repeat imaging prior to 
discharge, MRI showed e/o hyperenhancement c/w leptomenigeal 
involvement.  Both Optho and Neuro-onc evaluated the patient 
while in hospital.  After discussing the option, it was decided 
to do a lumbar puncture, and start high dose methotrexate for 
CNS involvement of lymphoma.

The patient's urine output and urine pH was monitored closely, 
and once methotrexate level was cleared and creat normalized 
(see below), he was dicharged home.

# MTX induced acute kidney injury: The patient had acute creat 
bump in the setting of high dose methotrexate despite having 
adequate urine output and urine pH between 7.5-8.  The patient's 
creat was trended and nephrotoxic agents were avoided and 
medications were renally dosed.  Renal was consulted; the 
patient's urine was also spun, and there was evidence of some 
crystals, as well as muddy brown casts.  It was thought that the 
patient could be having ATN in the setting of MTX therapy.  His 
creat was trending down upon discharge, and renal thought that 
it would continue to improve.  The patient should have his creat 
checked at his follow up visit on ___. 

# retinal vein occlusion: The patient had recent retinal vein 
occlusion.  Optho was consulted and the patient had Avastin 
injection on ___ in ___ clinic.  The patient will have 
outpatient follow up with Optho.  

# subarachnoid hemorrhage: The patient was found to have focal 
area of subarachnoid hemorrhage on MRI and head CT.  Unclear if 
this could be related to CNS involvement of his disease, though 
MRI was negative for any hyperenhancement which would suggest 
lymphoma.  He was monitored clinically.  The patient had repeat 
imaging as per Neuro-onc, specifically MRI with precontrast and 
postcontrast FLAIR series.  On repeat imaging, the patient was 
found to have hyperenhancement that was c/w leptomeningeal 
involvement.  

# Hypertension:  The patient is not on any medications at home, 
and his pressures were monitored while in house.  

Transitional Issues:
- The patient will have to have his creat checked as an 
outpatient. 
 
Medications on Admission:
allopurinol ___ mg daily
 
Discharge Medications:
1. allopurinol ___ mg Tablet Sig: One (1) Tablet PO DAILY 
(Daily).  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
primary diagnosis:
mantle cell lymphoma

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure taking care of you while you were hospitalized 
at ___.  You were admitted to the hospital for an MRI and 
chemotherapy.  You were seen by our eye doctors ___ 
___, and after a discussion, it was decided that 
you should get a lumbar puncture and initiate chemotherapy to 
help treat possibly lymphoma spread into your brain.

The eye doctors also ___ into your eye prior to 
your discharge. 

We did not make any changes to your medications.

You have follow up scheduled with Dr. ___ eye doctor, as 
listed below.  You will also need to follow up with Dr. ___ on 
___.  Please check your renal function at this 
visit.  
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-18 | hadm_id=28830371

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
___ Complaint:
Scheduled admission for high dose cyclophosphamide
 
Major Surgical or Invasive Procedure:
None

 
History of Present Illness:
___ year old man with mantle cell lymphoma/leukemia with CNS 
involvement who is being admitted for high dose cytoxan prior to 
stem cell mobilization.  He feels well and has no complaints.

Review of Systems:  
Denies fever, chills, night sweats, headache, vision changes, 
rhinorrhea, congestion, sore throat, cough, shortness of breath, 
chest pain, abdominal pain, nausea, vomiting, diarrhea, 
constipation, BRBPR, melena, hematochezia, dysuria, hematuria. 

PAST ONCOLOGIC HISTORY:  
Mr. ___ was noted for an elevated WBC count in ___. 
 He was going to follow up in the early part of ___ but had 
changed his PCP and was seen in ___ with increasing white 
blood count of ~35,000.  CT imaging done on ___, the 
results of which are not available.  PET/CT imaging on ___ 
showed mild to moderate FDG uptake within lymphadenopathy of the 
neck, bilateral axillae, retroperitoneal and inguinal areas.  
The spleen was diffusely enlarged with mild diffuse FDG uptake. 
Initial peripheral blood smear noted medium sized lymphocytes, 
no smudge cells, some cells (~10%) with more open chromatin and 
nucleoli.  The cells were CD ___ + with CD1 translocation felt 
consistent with mantle cell lymphoma. Because
of the high white count, there was concern for more aggressive 
leukemic component and he was initiated on CHOP on ___ 
with the plan to receive Rituxan with Dr. ___ primary 
oncologist. Around the same time of this workup, Mr. ___ was 
seeing his ophthalmologist for routine eye care, but also with 
noted changes of vision of the left eye.  He has an 
accommodating lens and was found to  have an occlusion of the 
distal branch of a retinal vein on the left.  Follow up from 
___ ophthalmology reported Choroidal cellular infiltrate in 
the left eye concerning for CNS involvement from his Mantle Cell 
lymphoma/leukemia.  He was admitted urgently on ___ for MRI 
imaging and LP, followed by high dose Methotrexate.  MRI imaging 
on ___ showed focal right occipital lobar sulcal 
FLAIR-hyperintensity concerning for subarachnoid hemorrhage, 
although leptomeningeal involvement was possible.  Repeat MRI 
imaging on ___ showed the previous FLAIR-signal 
abnormality but as it is seen only on the post-contrast FLAIR 
images, it is felt consistent with leptomeningeal enhancement, 
concerning for focal lymphomatous
spread.  LP done on ___ did not have adequate cells for
evaluation.  He was seen by Dr. ___ Neuro-Oncology as
well as Dr. ___ ophthalmology.  He received an 
intraocular Avastin injection on ___, second one on 
___ and ___ injection with laser treatment on ___. 

Because Mr. ___ has probable leukemic/blastic variant of 
mantle cell lymphoma, he is continuing with aggressive 
treatment. The plan has been to alternate R-CHOP with High dose 
Ara-C vs. R-DHAP with high dose methotrexate between each 
cycle(if tolerated by creatinine but the high dose methotrexate 
has been on hold).  He has completed treatment as outlined below 
and is now proceeding with autologous stem cell transplantation. 
 He underwent repeat bone marrow aspirate and biopsy on 
___ which did not show any evidence of mantle cell 
lymphoma/leukemia. Repeat LP was negative.  Echocardiogram on 
___ with EF of > 60%.  Pulmonary Function tests on 
___ with FVC 108%, FEV1 104%, and DLCO 89%.  

TREATMENT HISTORY:
 * ___ - C1 CHOP
 * ___ - Admitted urgently due to choroidal cellular 
infiltrate in the left eye concerning for CNS involvement from 
his Mantle Cell lymphoma/leukemia.  MRI imaging consistent with 
this. 
 * ___ - High dose methotrexate, complicated by acute renal 
insufficiency with creatinine peaking at 2.2 felt most likely 
from precipitation in the renal tubules.  Creatinine has 
trending downward, stabilizing at 1.5. Discharged on ___.
 * ___ and ___ - Received Rituxan in divided doses 
with mild reaction. 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due to his age and renal function; received 2 doses on ___, 1 
dose on ___ and 1 dose on ___.  On Neupogen support during 
nadir, required transfusion of red cells and platelets. 
 * ___ - C2 RCHOP 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due to age and renal function.  High dose MTX on hold with renal 
insufficiency.
 * ___ - C3 RCHOP
 * Restaging scan shows interval improvement of lymphoma. MRI of 
head with resolution of previous enhancement.  
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 due 
to age and renal function. 
 * ___ - Repeat LP and IT Ara-C given

 
Past Medical History:
- Mantle cell lymphoma/leukemia, HPI as above
- Heterozygous for Factor V Leiden and low Protein S activity of
39%, repeated on ___. 
- Hypertension
- Prostate hypertrophy 
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- s/p Appendectomy
- s/p Prostate biopsy (incisional)
- s/p Repair of deviated nasal septum

 
Social History:
___
Family History:
No lymphoma or leukemia in family. Mother had bone cancer, died 
at age ___ with also history of ___. Father died at age 
___ with h/o hypertension, stroke. One brother s/p CABG, stroke 
and ETOH use.
 
Physical Exam:
ADMISSION PHYSICAL EXAM
GENERAL - Well-appearing ___ yo M who appears comfortable, 
appropriate and in NAD  
HEENT - NC/AT, PERRL, EOMI, sclerae anicteric, MMM, OP clear  
NECK - supple
LUNGS - Lungs are clear to ausculatation bilaterally, moving air 
well and symmetrically, resp unlabored, no accessory muscle use  

HEART - RRR, normal S1/S2 without murmurs, rubs or gallops  
ABDOMEN - NABS, soft/NT/ND, no masses or HSM, no 
rebound/guarding  
EXTREMITIES - WWP, no c/c/e, 2+ peripheral pulses (radials, DPs) 
 
NEURO - awake, A&Ox3, CNs II-XII grossly intact, 

DISCHARGE PHYSICAL EXAM
VITALS - T 97.7 138/80 65 20 95%RA 
GENERAL - NAD, AAOx3, comfortable
HEENT - NC/AT, PERRL, EOMI, sclerae anicteric, MMM, OP clear  
LUNGS - CTAB, no w/r/r  
HEART - RRR, normal S1/S2 without murmurs, rubs or gallops  
ABDOMEN - NABS, soft/NT/ND, no masses or HSM, no 
rebound/guarding  
EXTREMITIES - WWP, no c/c/e, 2+ peripheral pulses (radials, DPs) 
 
NEURO - awake, A&Ox3
 
Pertinent Results:
ADMISSION LABS
___ 11:35AM   WBC-5.5 RBC-3.19* HGB-11.7* HCT-32.6* 
MCV-102* MCH-36.6* MCHC-35.9* RDW-19.6*
___ 11:35AM   NEUTS-80.0* LYMPHS-10.0* MONOS-8.0 EOS-1.5 
BASOS-0.5
___ 11:35AM   ALT(SGPT)-31 AST(SGOT)-27 LD(LDH)-172 ALK 
PHOS-59 TOT BILI-0.3
___ 11:35AM   ALBUMIN-4.5 CALCIUM-9.9 PHOSPHATE-4.4 
MAGNESIUM-2.2
___ 11:35AM   ___ PTT-33.1 ___
___ 11:35AM   UREA N-23* CREAT-1.2 SODIUM-143 POTASSIUM-4.3 
CHLORIDE-105 TOTAL CO2-30 ANION GAP-12
___ 06:01PM URINE  RBC-<1 WBC-2 BACTERIA-NONE YEAST-NONE 
EPI-<1
___ 06:01PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG 
GLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-7.0 
LEUK-TR

DISCHARGE LABS

___ 06:30AM BLOOD WBC-5.7 RBC-2.94* Hgb-10.6* Hct-29.9* 
MCV-102* MCH-36.0* MCHC-35.4* RDW-18.7* Plt ___
___ 06:30AM BLOOD Neuts-95.7* Lymphs-3.0* Monos-1.0* 
Eos-0.2 Baso-0
___ 06:30AM BLOOD Glucose-136* UreaN-23* Creat-1.1 Na-138 
K-4.1 Cl-105 HCO3-22 AnGap-15
___ 06:30AM BLOOD ALT-26 AST-24 LD(LDH)-146 AlkPhos-50 
TotBili-0.3
___ 06:30AM BLOOD Albumin-3.9 Calcium-9.3 Phos-3.7 Mg-1.___ year old man with mantle cell lymphoma/leukemia with CNS 
involvement who was admitted for high dose cytoxan prior to stem 
cell mobilization.

ACTIVE ISSUES
# Mantle Cell Lymphoma: Received high dose cyclophosphamide in 
preparation for autologous stem cell transplant.  He tolerated 
this well.  He was discharged the following morning with plan 
for daily Neupogen starting ___ in preparation for stem 
cell collection.  Acyclovir and Bactrim were continued 
throughout admission.  

CHRONIC ISSUES
# Retinal vein occlusion:  Stable; followed by Dr. ___ 
ophthalmology.   

# Hypertension:  Not on any medications at this time. 

TRANSITIONAL ISSUES
None

 
Medications on Admission:
Preadmission medications listed are correct and complete.  
Information was obtained from webOMR.
1. Ondansetron 8 mg PO Q8H:PRN nausea 
2. Allopurinol ___ mg PO DAILY 
3. Lorazepam 0.5-1 mg PO Q8H:PRN insomnia or nausea 
4. Acyclovir 400 mg PO Q12H 
5. Omeprazole 20 mg PO DAILY PRN indigestion 
6. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN bone pain 
7. Sulfameth/Trimethoprim DS 1 TAB PO MON, WEDS, FRI 
8. lactoperoxi-gluc oxid-pot thio *NF* 15 ml Mucous Membrane BID 


 
Discharge Medications:
1. Acyclovir 400 mg PO Q12H 
2. Allopurinol ___ mg PO DAILY 
3. Lorazepam 0.5-1 mg PO Q8H:PRN insomnia or nausea 
4. Omeprazole 20 mg PO DAILY PRN indigestion 
5. OxycoDONE (Immediate Release)  ___ mg PO Q4H:PRN bone pain 
6. Sulfameth/Trimethoprim DS 1 TAB PO MON, WEDS, FRI 
7. Dexamethasone 8 mg PO Q12H Duration: 2 Days 
RX *dexamethasone 4 mg 2 tablet(s) by mouth twice a day Disp #*6 
Tablet Refills:*0
8. lactoperoxi-gluc oxid-pot thio *NF* 15 ml Mucous Membrane BID 

9. Ondansetron 8 mg PO Q8H:PRN nausea 

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Mantle cell leukemia/lymphoma

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___,

It was a pleasure taking care of you while you were admitted at 
___.  You were admitted for high dose chemotherapy with 
Cytoxan in preparation for your upcoming transplant.  You 
tolerated the chemotherapy well and were discharged the next 
day.
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-15 | hadm_id=29441062

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
scheduled admission for ___  

 
Major Surgical or Invasive Procedure:
none

 
History of Present Illness:
Mr. ___ is a ___ recently diagnosed with mantle cell lymphoma 
with CNS involvement s/p C1D26 CHOP, C1D20 HD MTX who is 
presenting for HiDAC.  The patient was initially diagnosed with 
mantle cell lymphoma after being found to have an elevated white 
count in ___. Initial bone marrow biopsy found to have 
medium sized lymphocytes, no smudge cells, some cells (~10%) 
with more open chromatin and nucleoli. The cells were found to 
be CD ___ + with CD1 translocation.  His course was later 
complicated by retinal vein occlusion and subretinal deposits, 
concerning for CNS involvement, which is why he is s/p HD MTX. 

Of note, during most recent admission for HD MTX, the patient 
was noted to have ___, with creat peaking at 2.2.  The patient's 
baseline 1.1-1.2. 

Currently, the patient reports he feels well.  Does report some 
fatigue, but other than that, has no complaints.  Denies any 
mouth sores, no abdominal pain, no headaches or trouble seeing.  
Denies shortness of breath or chest pain/palpitations.  Denies 
any changes in his bowel movements.  No weakness.  

 
Past Medical History:
PAST ONCOLOGIC HISTORY:  
- Mantel Cell Lymphoma, recently diagnosed 2 weeks ago, with new 
CNS involvement, s/p R-CHOP (Cycle 1, Day 1 on ___, Day 2 on 
___

PAST MEDICAL HISTORY:  
- Hypertension
- Prostate hypertrophy
- Chronic lymphocytic leukemia  
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- s/p Appendectomy
- s/p Prostate biopsy (incisional)
- s/p Repair of deviated nasal septum

 
Social History:
___
Family History:
CABG, hyperlipidemia, mental retardation.

 
Physical Exam:
Admission PE:
VS: 98.6 142/86 72 20 98RA
General: younger than stated age, well appearing, alert and 
appropriate, NAD
HEENT: EOMI, moist mucous membranes  
CARDIAC: RRR, S1/S2, no murmurs/rubs/gallops appreciated  
LUNG: CTAB, no wheezes/rhonchi/crackles noted  
ABDOMEN: soft, nontender, nondistended, +BS  
EXT: warm, well perfused, no ___ edema, 2+ DP pulses  
Neuro: CN ___ grossly intact, normal muscle strength and 
sensation throughout, finger to nose and heel to shin normal

Discharge PE:

 
Pertinent Results:
Admission labs:

___ 09:00AM BLOOD WBC-3.3* RBC-3.28* Hgb-9.7* Hct-28.5* 
MCV-87 MCH-29.6 MCHC-34.0 RDW-15.7* Plt ___
___ 09:00AM BLOOD Neuts-49.3* ___ Monos-10.9 
Eos-1.6 Baso-0.8
___ 09:00AM BLOOD UreaN-29* Creat-1.6* Na-142 K-4.2 Cl-108 
HCO3-26 AnGap-12
___ 09:00AM BLOOD Glucose-106*
___ 09:00AM BLOOD ALT-22 AST-25 LD(LDH)-217 AlkPhos-55 
TotBili-0.3
___ 09:00AM BLOOD Albumin-4.2 Calcium-8.9 Phos-4.5 Mg-2.5 
UricAcd-8.2*

Discharge labs:

 
Brief Hospital Course:
Mr. ___ is a ___ recently diagnosed with mantle cell lymphoma 
with CNS involvement s/p C1D26 CHOP, C1D20 HD MTX, course c/b 
___ with creat now trending down, who is presenting for HiDAC.   


# Mantle cell lymphoma:  The patient is s/p R-CHOP and HD MTX 
which was complicated by ___.  It was decided that his regimen 
will also include alternative dosing of HiDAC as well, as per 
Dr. ___. Because of his recent ___, the patient got 
dose-reduced 1 gram dosing of his HiDAC, with creat being 
closely followed.  The patient was instructed to return to 
clinic the day after discharge for initiation of Neupogen, and 
agreed to return to clinic daily for Neupogen injections for as 
long as medically necessary.  The patient was also instructed to 
take allopurinol ___ mg daily. 

# Possible intra-ocular involvement: The patient has possible 
intra-ocular involvement of his lymphoma as evidenced by 
subretinal deposits on dilated exam.  As per Dr. ___ 
patient should get a vitreous biopsy in order to confirm the 
presence of disease in the eye prior to starting intraocular 
injections of methotrexate.  

# ___: The patient has ___ in the setting of HD-MTX. Because of 
this ___, he received dose reduced HiDAC.  His creat was trended 
and he was continued on IVF with his chemo orders.  Medications 
were renally dosed and nephrotoxic medications were avoided. 

# Hypertension: The patient's pressures were monitored while in 
house.  Addition of an anti-hypertensive agent can be considered 
as an outpatient. 

Transitional Issues:
- Whether the patient's insurance will cover his Neupogen 
injections will have to be addressed as an outpatient.  He will 
come into clinic daily for Neupogen injections daily in the 
meantime.
 
Medications on Admission:
none.
 
Discharge Medications:
1. allopurinol ___ mg Tablet Sig: 0.5 Tablet PO DAILY (Daily).  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Primary diagnosis:
mantle cell lymphoma

 
Discharge Condition:
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.
Mental Status: Clear and coherent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure taking care of you while you were hospitalized 
at ___.  You were admitted to the hospital for chemotherapy.  
You tolerated the chemotherapy well.  You will need to go to the 
___ on ___ for a Neupogen shot, and then will 
see Dr. ___ in ___ on ___.  You will need to 
return daily for neupogen shots in clinic.

We made the following changes to your medications:
START allopurinol ___ mg by mouth daily
START Neupogen injections daily
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-21 | hadm_id=29552764

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
Fatigue, malaise, cough
 
Major Surgical or Invasive Procedure:
None 

 
History of Present Illness:
___ year old gentleman with history of Mantle cell
lymphoma/leukemia with CNS involvement (choroidal infiltration 
in
the left eye) s/p auto transplant and Rituxan maintenance 
therapy
ending ___ with new diagnosis of recurrence, hypertension,
CVA/CRVO, SSS s/p PPM, pAF on Eliquis, and convulsive syncope 
who
presented from ___ for sepsis in setting of pneumonia.

Per chart review, patient had recent hospitalization from
___ for episode of convulsive syncope, at that time
with work up including unremarkable telemetry, pacemaker
interrogation, and EEG. CTH with interval development of a new
chronic left 
basal ganglia infarct since the prior examination, and MRI with
medial right occipital lobe FLAIR leptominingeal enhancement
similar to ___. He was unfortunately also found to have
recurrence of mantle cell lymphoma on bone marrow biopsy
(obtained after finding diffuse lymphadenopathy on CT chest). 

Per ED report, patient initially presented ___ to ___ with
generalized fatigue, malaise, and a cough, found to have a LL
pneumonia. Partial ED notes from ___ mention that he reported
fever to 101 at home. Flu swab reportedly negative. He received
IV vancomycin, cefepime, IVF and was transferred to ___ ED for
further evaluation. Prior to transport patient reportedly
hypotensive for which he received additional IVF- in total 2.1L
prior to arrival in our ED. Unfortunately there is only
incomplete paperwork available for review.

When discussing with patient- he reports that he was in his 
usual
state of health up until ___ days ago when he had an episode of
left leg heaviness when he was making pancakes for his 2
grandchildren. He noted that he had to hold onto objects while
walking, but then after lying down he noted that he regained his
strength such that he was able to walk upstairs without
assistance (which is his baseline). He denies any actual fall, 
no
headstrike. No weakness elsewhere, numbness, tingling. He also
reports that he has had several days of cough that is mildly
productive of sputum, no abdominal pain, nausea, vomiting, no
dysuria/hematuria. Of note, patient has history of CVA (L
putatmen/caudate) in ___ at that time with work up with CTA
neck only revealing right vertebral artery "diminutive" through
cervical course (occulusion vs hypoplasia) and a short segment 
of
occlusion/high-grade stenosis in right A2 segment of ACA with
distal reconstitution, and thought perhaps symptoms in setting 
of
bradycardia (he underwent pacemaker placement at that time).
 
Past Medical History:
ONCOLOGIC HISTORY:
 * ___ - C1 CHOP
 * ___ - Admitted urgently due to choroidal cellular
infiltrate in the left eye concerning for CNS involvement from
his Mantle Cell lymphoma/leukemia.  MRI imaging consistent with
this. 
 * ___ - High dose methotrexate, complicated by acute renal
insufficiency with creatinine peaking at 2.2 felt most likely
from precipitation in the renal tubules.  Creatinine has 
trending
downward, stabilizing at 1.5. Discharged on ___.
 * ___ and ___ - Received Rituxan in divided doses
with mild reaction. 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to his age and renal function; received 2 doses on ___, 1 dose
on ___ and 1 dose on ___.  On Neupogen support during nadir,
required transfusion of red cells and platelets.
 * ___ - C2 RCHOP 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to age and renal function.  High dose MTX on hold with renal
insufficiency.
 * ___ - C3 RCHOP
 * Restaging scan shows interval improvement of lymphoma.  MRI 
of
head with resolution of previous enhancement.  
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 due
to age and renal function. 
 * ___ - Repeat LP and IT Ara-C given
 * ___ - High dose cytoxan for stem cell mobilization
 * ___ - Started stem cell collections with Neupogen and
Mozibil and collected ~ 5 million CD34 cells/kg over 4 days.
 .
PAST MEDICAL HISTORY:  
- Mantle cell lymphoma/leukemia
- Heterozygous for Factor V Leiden and low Protein S activity of
39%, repeated on ___, now normal 
- Hypertension
- Prostate hypertrophy 
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus
- Status post appendectomy
- Status post prostate biopsy (incisional)
- Status post repair of deviated nasal septum

 
Social History:
___
Family History:
No lymphoma or leukemia in family. Mother had bone cancer, died 
at age ___ with also history of ___. Father died at age 
___ with h/o hypertension, stroke. One brother s/p CABG, stroke 
and ETOH use.
 
Physical Exam:
ADMISSION PHYSICAL EXAM:
========================
GEN: Pleasant elderly gentleman lying in bed in no acute 
distress
EYES:  PERRLA, EOMI
HENNT:  MMM, anterior cervical and axillary lymphadenopathy
CV: Regular rate, irregular rhythm, no m/r/g appreciated, cap
refill <2s
RESP: ?Faint crackles at L base, no increased work of breathing,
else clear  
GI:  Soft, nt, nd
SKIN: Erythema around bilateral cheeks  
NEURO: AO x 3, CN II-XII intact, strength ___ throughout, no
pronator drift 
ACCESS: pIV

DISCHARGE PHYSICAL EXAM: 
========================
Vitals: Reviewed in Metavision
GEN: Pleasant elderly gentleman lying in bed in no acute 
distress
EYES:  PERRLA, EOMI
HENNT:  MMM, anterior cervical and axillary lymphadenopathy
CV: Regular rate, irregular rhythm, no m/r/g appreciated, cap
refill <2s
RESP: ?Faint crackles at L base, no increased work of breathing,
else clear  
GI:  Soft, nt, nd
SKIN: Erythema around bilateral cheeks  
NEURO: AO x 3, CN II-XII intact, strength ___ throughout, no
pronator drift 
ACCESS: pIV
 
Pertinent Results:
ADMISSION LABS:
==============
___ 01:52AM BLOOD WBC-16.9* RBC-3.97* Hgb-12.4* Hct-38.1* 
MCV-96 MCH-31.2 MCHC-32.5 RDW-13.0 RDWSD-45.8 Plt ___
___ 01:52AM BLOOD Neuts-86.5* Lymphs-3.2* Monos-9.0 
Eos-0.0* Baso-0.4 Im ___ AbsNeut-14.65* AbsLymp-0.54* 
AbsMono-1.53* AbsEos-0.00* AbsBaso-0.06
___ 01:52AM BLOOD Glucose-98 UreaN-29* Creat-1.6* Na-142 
K-4.1 Cl-106 HCO3-20* AnGap-16
___ 01:52AM BLOOD ALT-22 AST-28 AlkPhos-67 TotBili-0.9
___ 01:52AM BLOOD Lipase-15
___ 01:52AM BLOOD cTropnT-<0.01
___ 01:52AM BLOOD Albumin-3.8
___ 02:04AM BLOOD Lactate-3.7*
___ 05:01AM BLOOD Lactate-2.3*

STUDIES:
=======
OSH CXR 

MICRO: 
======
____________________________________________
___ 8:31 pm SPUTUM      Source: Expectorated. 

                            **FINAL REPORT ___

   GRAM STAIN (Final ___: 
      <10 PMNs and >10 epithelial cells/100X field. 
      Gram stain indicates extensive contamination with upper 
respiratory
      secretions. Bacterial culture results are invalid. 
      PLEASE SUBMIT ANOTHER SPECIMEN. 

   RESPIRATORY CULTURE (Final ___: 
      TEST CANCELLED, PATIENT CREDITED. 
__________________________________________________________
___ 5:52 pm Rapid Respiratory Viral Screen & Culture
      Source: Nasopharyngeal swab. 

                            **FINAL REPORT ___

   Respiratory Viral Culture (Final ___: 
      TEST CANCELLED, PATIENT CREDITED. 
      Inadequate specimen for respiratory viral culture. 
      PLEASE SUBMIT ANOTHER SPECIMEN. 

   Respiratory Viral Antigen Screen (Final ___: 
      Less than 60 columnar epithelial cells;. 
      Inadequate specimen for DFA detection of respiratory 
viruses.. 
      Interpret all negative DFA and/or culture results from 
this specimen
      with caution.. 
      Negative results should not be used to discontinue 
precautions.. 
      Recommend new sample be submitted for confirmation.. 
      Refer to respiratory viral culture and/or Influenza PCR 
(results
      listed under "OTHER" tab) for further information.. 
__________________________________________________________
___ 1:00 pm URINE      Source: ___. 

                            **FINAL REPORT ___

   Legionella Urinary Antigen  (Final ___: 
      NEGATIVE FOR LEGIONELLA SEROGROUP 1 ANTIGEN. 
           (Reference Range-Negative). 
      Performed by Immunochromogenic assay. 
      A negative result does not rule out infection due to other 
L.
      pneumophila serogroups or other Legionella species. 
Furthermore, in
      infected patients the excretion of antigen in urine may 
vary. 
__________________________________________________________
___ 1:00 pm URINE      Source: ___. 

                            **FINAL REPORT ___

   URINE CULTURE (Final ___:    NO GROWTH. 
__________________________________________________________
___ 8:00 am MRSA SCREEN      Source: Nasal swab. 

   MRSA SCREEN (Pending): 
__________________________________________________________
___ 2:02 am BLOOD CULTURE

   Blood Culture, Routine (Pending):    No growth to date. 
__________________________________________________________
___ 1:52 am BLOOD CULTURE

   Blood Culture, Routine (Pending):    No growth to date. 

DISCHARGE LABS: 
==============
___ 07:01AM BLOOD WBC-8.0 RBC-3.40* Hgb-10.5* Hct-31.9* 
MCV-94 MCH-30.9 MCHC-32.9 RDW-13.3 RDWSD-45.9 Plt ___
___ 07:01AM BLOOD Glucose-103* UreaN-19 Creat-1.1 Na-148* 
K-4.1 Cl-114* HCO3-21* AnGap-13
___ 07:01AM BLOOD Calcium-8.0* Phos-2.0* Mg-1.9
___ 01:52AM BLOOD IgG-555* IgA-168 IgM-___ year old gentleman with history of mantle cell lymphoma s/p 
auto transplant with recurrence, hypertension, CVA/CRVO, SSS s/p 
PPM, pAF on Eliquis, and convulsive syncope who presented from 
home for septic shock from pneumonia. 

ACUTE ISSUES 
=============== 
# SEPTIC SHOCK
# LLL PNEUMONIA
The patient presented with fever, leukocytosis, elevated 
lactate, hypotension and chest x-ray concerning for left lower 
lobe infiltrate concerning for sepsis secondary to pneumonia. 
Given his recent hospitalization and relative immunosuppression 
in the setting of his lymphoma he was covered broadly initially 
with vancomycin, cefepime and azithromycin. He was briefly on 
vasopressors and was given IV fluids. He was switched to 
cefpodoxime/azithromycin on day prior to discharge. He was 
discharged to complete a course of 5 days of azithromycin and 7 
days of cefpodoxime to end on ___.

# ___
Baseline Cr 1.0, on admission up to 1.6, likely prerenal in the 
setting of sepsis. With IVF and antibiotics, this decreased to 
close his baseline on discharge (1.1).

# RECURRENT MANTLE CELL LYMPHOMA
MB and LN biopsy ___ with recurrence of mantle cell 
lymphoma. Patient scheduled for PET scan and further treatment 
as outpatient. Immunoglobulins were measured and were remarkable 
for mild hypogammaglobulinemia. Hematology/oncology was 
consulted. He continued acyclovir prophylaxis.

# EPISODE OF L LEG WEAKNESS
He had an episode of left lower extremity weakness that could 
have occurred in the setting of hypotension and likely 
represents recrudescence of his prior stroke symptoms. This 
quickly resolved with resolution of his septic shock. 

CHRONIC ISSUES 
=============== 
# ATRIAL FIBRILLATION
# SSS S/P PPM
Apixaban was held when his creatinine function was diminished in 
setting ___ but resumed with recovered renal function. While 
apixaban was held he was continued on heparin drip.
# HYPERTENSION: Held home losartan 50 mg daily
# HYPERLIPIDEMIA: Continue atorvastatin 80 mg daily
# BPH: Holding home tamsulosin I/s/o hypotension
# OSA: On nocturnal CPAP at home, unclear settings

TRANSITIONAL ISSUES: 
[] He was discharged to complete a course of 5 days of 
azithromycin and 7 days of Cefpodoxime to end on ___.
[] He should have short term follow up with heme/onc to discuss 
his recurrent mantle cell lymphoma and potential therapy 
(scheduled for ___. 
[] Monitor BPs outpatient; prior home losartan was held on 
discharge given hypotension this admission (on discharge SBP 
100-120s off this medication)- consider restart at heme/onc or 
PCP follow up

#CODE STATUS: Full 
#EMERGENCY CONTACT: ___: brother
Phone number: ___
 
___ on Admission:
The Preadmission Medication list is accurate and complete.
1. Acyclovir 400 mg PO Q12H 
2. Albuterol Inhaler 2 PUFF IH Q6H:PRN sob 
3. Apixaban 5 mg PO BID 
4. FoLIC Acid 1 mg PO DAILY 
5. Losartan Potassium 50 mg PO DAILY 
6. Tamsulosin 0.4 mg PO QHS 
7. Atorvastatin 80 mg PO QPM 
8. Cyanocobalamin 1000 mcg PO EVERY OTHER DAY 
9. Multivitamins 1 TAB PO DAILY 

 
Discharge Medications:
1.  Azithromycin 250 mg PO DAILY Duration: 4 Doses 
RX *azithromycin 250 mg 1 tablet(s) by mouth daily Disp #*4 
Tablet Refills:*0 
2.  Cefpodoxime Proxetil 400 mg PO Q12H Duration: 6 Days 
RX *cefpodoxime 200 mg 2 tablet(s) by mouth twice a day Disp 
#*24 Tablet Refills:*0 
3.  Acyclovir 400 mg PO Q12H  
4.  Albuterol Inhaler 2 PUFF IH Q6H:PRN sob  
5.  Apixaban 5 mg PO BID  
6.  Atorvastatin 80 mg PO QPM  
7.  Cyanocobalamin 1000 mcg PO EVERY OTHER DAY  
8.  FoLIC Acid 1 mg PO DAILY  
9.  Multivitamins 1 TAB PO DAILY  
10.  Tamsulosin 0.4 mg PO QHS  
11. HELD- Losartan Potassium 50 mg PO DAILY  This medication was 
held. Do not restart Losartan Potassium until you see your PCP

 
___:
Home
 
Discharge Diagnosis:
Septic shock
Pneumonia

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure being involved in your care!

You were hospitalized because you had a pneumonia.
You were given antibiotics to treat your pneumonia.
Please complete these antibiotics after leaving the hospital as 
described below.
Please go to all of your follow-up appointments including with 
your oncologist Dr. ___.

We wish you the best!
Your ___ Team 
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=17093667-DS-17 | hadm_id=29697468

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
___ Complaint:
mantle cell lymphoma/leukemia, admission for C2 HiDaC
 
Major Surgical or Invasive Procedure:
none

 
History of Present Illness:
Mr. ___ was noted for an elevated WBC count in ___. 
 In ___ his white cell count increased to ~35,000. PET/CT 
imaging on ___ showed mild to moderate FDG uptake within 
lymphadenopathy of the neck, bilateral axillae, retroperitoneal 
and inguinal areas.  The spleen was diffusely enlarged with mild 
diffuse FDG uptake. Initial peripheral blood smear noted medium 
sized lymphocytes, no smudge cells, some cells (~10%) with more 
open chromatin and nucleoli.  The cells were CD ___ + with CD1 
translocation felt consistent with mantle cell lymphoma. Because 
of the high white count, there was concern for more aggressive 
leukemic component and he was initiated on CHOP on ___ 
with the plan to receive Rituxan with Dr. ___ primary 
oncologist at the time.

Around the same time of this workup, Mr. ___ was seeing his 
ophthalmologist for routine eye care, but also with noted 
changes of vision of the left eye.  He has an accommodating lens 
and was found to  have an occlusion of the distal branch of a 
retinal vein on the left.  Follow up from ___ ophthalmology 
reported Choroidal  cellular infiltrate in the left eye 
concerning for CNS involvement from his Mantle Cell 
lymphoma/leukemia.  He was admitted urgently on ___ for MRI 
imaging and LP, followed by high dose ethotrexate.  MRI imaging 
on ___ showed focal right occipital lobar sulcal 
FLAIR-hyperintensity concerning for subarachnoid hemorrhage, 
although leptomeningeal involvement was possible.  Repeat MRI 
imaging on ___ showed the previous FLAIR-signal 
abnormality but as it is seen only on the post-contrast FLAIR 
images, it is felt consistent with leptomeningeal enhancement, 
concerning for focal lymphomatous spread.  LP done on ___ 
did not have adequate cells for evaluation.  He was seen by Dr. 
___ Neuro-Oncology as well as Dr. ___ 
ophthalmology.  He received an intraocular Avastin injection on 
___ and a second one on ___.  He will be due for ___ 
injection on ___.

Because Mr. ___ has probable leukemic/blastic variant of 
mantle cell lymphoma, he is continuing with aggressive 
treatment. The plan is to alternate R-CHOP with High dose Ara-C 
vs. R-DHAP with high dose methotrexate between each cycle(if 
tolerated by creatinine).

Mr. ___ is being admitted today for his next treatment with 
high dose Ara-C.

Treatment history:
* ___ - C1 CHOP
 * ___ - Admitted urgently due to choroidal cellular
infiltrate in the left eye concerning for CNS involvement from
his Mantle Cell lymphoma/leukemia.  MRI imaging consistent with
this. 
 * ___ - High dose methotrexate, complicated by acute renal
insufficiency with creatinine peaking at 2.2 felt most likely
from precipitation in the renal tubules.  Creatinine has 
trending
downward, stabilizing at 1.5. Discharged on ___.
 * ___ and ___ - Received Rituxan in divided doses
with mild reaction. 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to his age and renal function; received 2 doses on ___, 1 dose
on ___ and 1 dose on ___.  On Neupogen support during nadir,
required transfusion of red cells and platelets.
 * ___ - C2 RCHOP 
 * ___ - High dose Ara-C.  Dose decreased to 1000 mg/m2 
due
to age and renal function.  High dose MTX on hold with renal
insufficiency.
 * ___ - C3 RCHOP

 
Past Medical History:
- Mantle cell lymphoma/leukemia
- Heterozygous for Factor V Leiden and low Protein S activity of
39%, repeated on ___. 
- Hypertension
- Prostate hypertrophy 
- Arthritis  
- Erectile dysfunction  
- Diverticulosis  
- Disc degeneration, lumbar  
- Sensorineural hearing loss with longstanding tinnitus

Surgical history:
- Appendectomy
- Prostate biopsy (incisional)
- Repair of deviated nasal septum

 
Social History:
___
Family History:
No lymphoma or leukemia in family. Mother had bone cancer, died 
at age ___ she also had ___ disease. Father died at age 
___ with h/o hypertension and stroke. One brother s/p CABG, 
stroke and ETOH use. He has three children, one has diabetes, 
the others are healthy. He has two siblings, one suffered brain 
injury after childhood infection. 
 
Physical Exam:
VS: 97.5 134/72 72 18  oxygen saturation 98% on room air.
GENERAL:  Well-appearing older gentleman in no acute distress.
VITAL SIGNS: Performance status is %90.
HEENT: PERRL, conjunctiva pale, anicteric sclerae, nose clear, 
oropharynx within normal limits  
NECK:  Supple.
LYMPHATICS:  There is no cervical, infraclavicular, or 
supraclavicular adenopathy appreciated. 
LUNGS: Fine rales located bilaterally at lung bases, no 
wheezes/rhonchi  
HEART:  Regular rate and rhythm without murmurs, rubs, or 
gallops.
ABDOMEN:  Soft, nontender, and nondistended with normal bowel
sounds and without hepatosplenomegaly or other masses 
appreciated.
EXTREMITIES:  Without edema.
SKIN:  No rashes. 
NEURO: CNII-XII intact, gait normal, no tremor on signature, 
finger to nose within normal limits

 
Pertinent Results:
On admission:
___ 11:05AM BLOOD WBC-3.2*# RBC-3.04* Hgb-10.4* Hct-29.4* 
MCV-97 MCH-34.1* MCHC-35.2* RDW-19.8* Plt ___
___ 11:05AM BLOOD Neuts-65 Bands-0 ___ Monos-12* 
Eos-1 Baso-2 ___ Metas-1* Myelos-0
___ 11:05AM BLOOD ___ PTT-31.7 ___
___ 11:05AM BLOOD UreaN-24* Creat-1.3* Na-140 K-4.6 Cl-104 
HCO3-27 AnGap-14
___ 11:05AM BLOOD ALT-20 AST-26 LD(LDH)-183 AlkPhos-50 
TotBili-0.4
___ 11:05AM BLOOD Albumin-4.6 Calcium-9.8 Phos-5.1* Mg-2.4 
UricAcd-6.2

On discharge:

___ 07:40AM BLOOD WBC-2.8* RBC-2.47* Hgb-8.4* Hct-24.3* 
MCV-98 MCH-34.2* MCHC-34.7 RDW-19.6* Plt ___
___ 07:40AM BLOOD Neuts-93.1* Lymphs-2.9* Monos-3.8 Eos-0.1 
Baso-0
___ 07:40AM BLOOD Plt ___
___ 07:40AM BLOOD Glucose-120* UreaN-25* Creat-1.0 Na-142 
K-4.2 Cl-108 HCO3-24 AnGap-14
___ 07:40AM BLOOD ALT-15 AST-16 AlkPhos-41 TotBili-0.3
___ 07:40AM BLOOD Calcium-9.3 Phos-4.6* Mg-2.2
 
Brief Hospital Course:
Mr. ___ hospital course was uneventful. He received HiDaC 
per his primary oncologist's orders. No adverse reactions to the 
the cytarabine were noted. He received three times daily steroid 
eye drops which he is to continue for 48 hours after his 
discharge. His cerebellar exam remained within normal limits 
througout his hospital stay. He did not experience any nausea or 
vomiting. He remained afebrile throughout his entire hospital 
stay. He denied fever, chills, headache, shortness of breath, 
chest pain, nausea, vomiting, diarrhea, rash and bruising on 
admission and discharge. Home medications were continued during 
his hospitalization. He is to follow up at the ___ 7 out 
patient clinic 24 hours after discharge for cell counts and 
Neupogen.
 
Medications on Admission:
Preadmission medications listed are correct and complete.  
Information was obtained from PatientwebOMR.
1. Omeprazole 20 mg PO DAILY:PRN indigestion 
2. Allopurinol ___ mg PO DAILY 
3. Clotrimazole Cream 1 Appl TP BID:PRN rash 
apply to affected area twice daily 
4. Lorazepam 0.5-1 mg PO TID:PRN nausea/anxiety 
5. Ondansetron 8 mg PO Q8H:PRN nausea 
6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) 
7. Acyclovir 400 mg PO DAILY 

 
Discharge Medications:
1. Acyclovir 400 mg PO DAILY 
2. Allopurinol ___ mg PO DAILY 
3. Clotrimazole Cream 1 Appl TP BID:PRN rash 
apply to affected area twice daily 
4. Lorazepam 0.5-1 mg PO TID:PRN nausea/anxiety 
5. Omeprazole 20 mg PO DAILY:PRN indigestion 
6. Sulfameth/Trimethoprim DS 1 TAB PO 3X/WEEK (___) 
7. Ondansetron 8 mg PO Q8H:PRN nausea 
8. PrednisoLONE Acetate 1% Ophth. Susp. 1 DROP BOTH EYES TID 
continue 48 hours after last dose of cytarabne 

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Primary diagnosis
Mantle cell leukemia/lymphoma

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure to take care of you at ___ 
___. You were admitted in order to receive 
chemotherapy for your lymphoma/leukemia. You tolerated the 
chemotherapy very well and experienced no adverse side effects. 
Please take your medications as prescribed and followup with the 
appointments below. You will need to start taking Neupogen 24 
hours after discharge. As your white blood cell count drops we 
recommend you avoid large crowds and ill relatives/friends. If 
you have any further questions feel free to contact your ___ 
providers.
 
Followup Instructions:
___
